

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau



B22  
Attachments  
of 4

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification <sup>7</sup> : <b>C12N 15/12, 1/21, C07K 14/505, A61K 47/48, 38/18, A01K 67/027, A61P 7/06</b>		A2	(11) International Publication Number: <b>WO 00/32772</b>
		(43) International Publication Date: <b>8 June 2000 (08.06.00)</b>	
(21) International Application Number: <b>PCT/US99/27801</b>		(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).	
(22) International Filing Date: <b>23 November 1999 (23.11.99)</b>		<b>Published</b> <i>Without international search report and to be republished upon receipt of that report.</i>	
(30) Priority Data: <b>60/110,289 30 November 1998 (30.11.98) US</b>			
(71) Applicant (for all designated States except US): <b>ELI LILLY AND COMPANY [US/US]; Lilly Corporate Center, Indianapolis, IN 46285 (US).</b>			
(72) Inventors; and (75) Inventors/Applicants (for US only): <b>BEALS, John, Michael [US/US]; 6710 Bluffridge Parkway, Indianapolis, IN 46278-1853 (US). GLAESNER, Wolfgang [DE/US]; 7512 Fieldstone Court, Indianapolis, IN 46254 (US). MICANOVIC, Radmilla [US/US]; 7126 White Oak Trail, Indianapolis, IN 46236 (US). MILLICAN, Rohn, Lee, Jr. [US/US]; 5319 Deer Creek Avenue, Indianapolis, IN 46254 (US). WITCHER, Derrick, Ryan [US/US]; 10898 Parrot Court, Fishers, IN 46038 (US).</b>			
(74) Agents: <b>STEWART, Mark, J. et al.; Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285 (US).</b>			
(54) Title: <b>ERYTHROPOIETIC COMPOUNDS</b>			
(57) Abstract <p>The present invention addresses the need for better pharmaceutical agents for treating anemias by providing polymer derivatized non-glycosylated erythropoietic compounds which show stability and bioactivity <i>in vivo</i>. The invention further provides methods for preparing these derivatized proteins which involves the use of a linkerless aldehyde modification process.</p>			

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

### ERYTHROPOIETIC COMPOUNDS

The present invention is in the field of human medicine, particularly in the treatment of conditions  
5 treatable by stimulation of erythropoiesis, such as anemia. More specifically, the invention relates to polymer-derivatized, non-glycosylated proteins that cause an increase in blood hematocrit when administered to a patient.

10 Anemia is a condition characterized by a lower than normal volume or number of red blood cells, which are also known as erythrocytes, in the blood. One measure of the volume of red blood cells in blood is the hematocrit measurement. Blood hematocrit is the ratio, commonly  
15 expressed as a percentage, of the volume of packed cells in a sample to the total volume of the sample. Normal hematocrit levels range between 36% and 53%. Generally, a blood hematocrit below 36% is indicative of anemia.

Anemia is wide-spread in all societies, frequently  
20 associated with such conditions as renal failure, beta thalassemia, pregnancy, menstrual disorders, spinal cord injury, acute blood loss, hypoxia, aging, HIV infection associated with AZT therapy, and different neoplastic disease states accompanied by abnormal erythropoiesis, among  
25 many others.

Red blood cells are continuously being formed and destroyed in the body. Anemia arises when formation cannot keep pace with the destruction and loss of red blood cells.

- 2 -

Therapy of anemia is directed toward either reducing destruction and loss of red blood cells or toward replacing or increasing the formation of red blood cells, or both. An object of the present invention is to increase the formation of red blood cells.

Red blood cell formation occurs through a complex process known as erythropoiesis. This process, which occurs in the bone marrow, begins when a fraction of primitive multi-potent hematopoietic stem cells becomes committed to the red blood cell lineage. The stem cells first form burst forming units-erythroid (BFU-E), then in succession, colony-forming units-erythroid (CFU-E), normoblasts, erythroblasts, reticulocytes, and finally mature erythrocytes. Because of its complexity and essentiality, many control systems are needed to properly regulate erythropoiesis. Erythropoietin is one such control.

Erythropoietin (EPO) is a hormone that stimulates erythropoiesis. EPO is produced in the kidneys, is secreted into the blood stream, and stimulates the differentiation of precursor cells into erythrocytes in the bone marrow. The mechanism by which EPO stimulates erythropoiesis involves the binding of EPO to specific cell-surface receptors. Activation of the EPO receptor triggers intracellular signaling events including phosphorylation of the receptor followed by activation of the JAK-STAT, RAS, and PI3 kinase pathways. These signaling pathways trigger cells to undergo proliferation and differentiation and to block apoptosis.

EPO is a glycoprotein, having a protein portion and a carbohydrate portion. The protein portion of the predominant allelic variant of human EPO consists of 166 amino acids, and the sequence is known. EPO has been produced by recombinant DNA techniques (rHuEPO). Recombinant human EPO produced in Chinese Hamster Ovary (CHO) cells and other cell lines has only 165 amino acids,



- 3 -

lacking an arginine at position 166 [L. Owers-Narhi, et al., *J. of Biol. Chem.* 266:23022-23026 (1991)].

Human EPO has an apparent molecular weight of around 30.4 kDa. About 40% of the apparent molecular weight of EPO is due to carbohydrate. EPO has three N-linked oligosaccharide chains at amino acid positions 24, 38, and 83 and one O-linked oligosaccharide chain at position 126 of the mature protein. A high degree of heterogeneity in the branching and sialic acid content has been observed both at each N-linked glycosylation site and between sites.

The role of carbohydrate is complex. Studies have shown that proper glycosylation of specific sites is critical for proper biosynthesis and secretion of EPO. It is thought to promote correct folding during protein expression, and to protect EPO and recombinant glycosylated erythropoietic proteins from degradation during their biosynthesis, secretion, and circulation.

The carbohydrate portion of the molecule also has a great influence on *in vivo* activity. Certain processes that remove EPO and recombinant glycosylated erythropoietic proteins from the circulation are affected by the structure of the carbohydrate attached to EPO. Various studies have shown that the removal of terminal sialic acids from EPO destroys its *in vivo* activity. This is due in part to the fact that desialylated EPO is cleared from the circulation much faster than fully sialylated EPO. On the other hand, the *in vitro* activity of EPO actually increases with desialylation. This is most likely due to an increased affinity for the receptor.

Several pharmaceutical products contain recombinant glycosylated erythropoietic proteins. Although none of these proteins have exactly the same amino acid or carbohydrate structure as does human EPO, they differ very little structurally from human EPO, and have been found to

- 4 -

be effective therapeutically for treating certain anemias. However, these recombinant glycosylated erythropoietic proteins have not been optimized as therapeutic entities.

For example, these proteins must be administered  
5 intravenously or subcutaneously at fairly frequent intervals in order to maintain their stimulation of erythropoiesis. The recombinant molecule's natural properties limit the performance of the drug to traditional drug delivery systems. It would benefit the treatment of anemia, and  
10 reduce the discomfort and inconvenience associated with known recombinant glycosylated erythropoietic proteins to provide a pharmaceutical agent that could be administered less frequently, optionally by alternate routes of administration, and that would be more stable in order to  
15 permit longer-term storage. Additional benefits of longer-action would be a more natural pharmacokinetic profile, extended efficacy beyond the maximal reimbursement hematocrit level of 36, and potentially, reduction of adverse events such as hypertension. Thus, a need exists to  
20 develop agents that stimulate erythropoiesis, are more optimal in duration of effect, and are more stable pharmaceutically.

One approach has been to alter the carbohydrate content or structure of recombinant glycosylated erythropoietic  
25 proteins, e.g., novel erythropoiesis stimulating protein (NESP). Adding additional sites for glycosylation might be expected to enhance the stability of EPO in vivo and extend its half-life in the circulation. Additional glycosylation, however, is not necessarily a good approach in each case  
30 because it might result in a molecule less able to bind to the EPO receptor or more likely to be removed from the circulation by glycoprotein clearance mechanisms, and therefore, less suited to stimulate erythropoiesis. An

- 5 -

additional concern is that increasing glycosylation of EPO may negatively impact bioavailability of delivered protein.

Proteins are often administered using parenteral, pulmonary, oral, nasal, or transdermal methodologies.

5 Consequently, the quantity of material administered needs to be altered to offset complications associated with reduced bioavailability, altered pharmacokinetics, and altered pharmacodynamics. Furthermore, the demands of exogenous administration require protein properties not necessarily  
10 intrinsic in the native protein, such as solubility that exceed *in vivo* concentrations by an order of magnitude or greater. Finally, the formulation demands of an exogenously-administered therapeutic protein, necessary to elicit an *in vivo* response, can adversely impact the  
15 toxicological effect of the macromolecule.

To circumvent these problems and address the need for better pharmaceutical agents for treating anemias, non-glycosylated erythropoietic proteins derivatized with polyethylene glycol, were invented. Surprisingly, such  
20 molecules have been found to retain the ability of EPO to increase hematocrit levels *in vivo*.

An article by Francis, et al., suggests that the methods of the present invention result in an EPO molecule that has low bioactivity. *Intl. J. Hem.* (1998) 68:1-18.  
25 The authors state that the process of the present invention, using PEG-acetaldehyde as the activated polymer, results in very poor conservation of activity when wild-type EPO is modified. Francis, et al., do suggest, however, that tresylmonomethoxy-polyethyleneglycol (TMPEG) may be used to  
30 PEGylated GM-CSF and non-glycosylated wild type human erythropoietin. Yet, no methods regarding specific conditions necessary to maintain *in vivo* bioactivity and at the same time promote PEGylation are provided. The authors also do not characterize any of the non-glycosylated

- 6 -

PEGylated EPO proteins that were produced nor do they discuss any of the non-glycosylated analogs claimed in the present invention. The reference suggests only that it is possible to maintain *in vitro* activity from non-glycosylated PEGylated EPO. Yet, as discussed extensively below, whether a particular PEGylated protein has *in vitro* activity is essentially irrelevant with respect to whether that protein can function *in vivo*.

Contrary to the teachings by Francis, et al., however, the present invention provides polymer-derivatized non-glycosylated erythropoietic compounds that can be produced using a linkerless aldehyde modification process and that show stability and bioactivity *in vivo*.

In one aspect, the present invention includes non-glycosylated proteins of the Formula (I):

(SEQ ID NO:1)

```

-2  -1
Xaa Xaa
20  1      5      10      15
Ala Pro Pro Arg Leu Ile Cys Asp Ser Arg Val Leu Glu Arg Tyr Leu

25      20      25      30
Leu Glu Ala Lys Glu Ala Glu Xaa Ile Thr Thr Gly Cys Ala Glu His

35      40      45
Cys Ser Leu Asn Glu Xaa Ile Thr Val Pro Asp Thr Lys Val Asn Phe

50      55      60
30 Tyr Ala Trp Lys Arg Met Glu Val Gly Gln Gln Ala Val Glu Val Trp

65      70      75      80
Gln Gly Leu Ala Leu Leu Ser Glu Ala Val Leu Xaa Gly Gln Ala Leu

35      85      90      95
Leu Val Xaa Ser Ser Gln Pro Xaa Glu Pro Leu Gln Leu His Val Asp

100      105      110
40 Lys Ala Val Ser Gly Leu Arg Ser Leu Thr Thr Leu Leu Arg Ala Leu

115      120      125
Gly Ala Gln Lys Glu Ala Ile Ser Pro Pro Asp Ala Ala Xaa Ala Ala

```

- 7 -

130                      135                      140  
 Pro Leu Arg Thr Ile Thr Ala Asp Thr Phe Xaa Lys Leu Phe Arg Val  
 145                      150                      155                      160  
 5 Tyr Ser Asn Phe Leu Arg Gly Lys Leu Xaa Leu Tyr Thr Gly Glu Ala  
 165  
 Cys Arg Thr Gly Asp Xaa (I)

10 wherein:

Xaa at position -2 is absent or Met;  
 Xaa at position -1 is absent or is Ala, Cys, Asp, Glu,  
 Phe, Gly, His, Ile, Leu, Met, Asn, Gln, Arg, Ser, Thr, Val,  
 Trp, or Tyr;  
 15 Xaa at position 24 is Asn, Lys or Glu;  
 Xaa at position 38 is Asn, Lys or Glu;  
 Xaa at position 76 is Arg or Glu;  
 Xaa at position 83 is Asn, Lys or Glu;  
 Xaa at position 88 is Trp, Lys, Pro, or Arg;  
 20 Xaa at position 126 is Ser, Thr, Lys or Glu;  
 Xaa at position 139 is Arg or Glu;  
 Xaa at position 154 is Lys or Glu; and  
 Xaa at position 166 is Arg, absent, or any other amino  
 acid.

25

Non-glycosylated erythropoietin analogs include  
 proteins selected from the group consisting of: a) NGE; b)  
 NGE[5E]; c) MR-NGE; d) MR-NGE-88E; e) MR-NGE-88K; f) MR-NGE-  
 88P; g) MR-NGE-88S; h) MR-NGE[4E]; i) MR-NGE[5E]; j) MR-  
 30 NGE[5K]; k) MR-NGE[W5E]; and l) MR-NGE[W5K]. These Non-  
 glycosylated erythropoietin analogs may have any amino acid  
 at position 166 or may have amino acid 166 deleted.

These non-glycosylated EPO analogs do not themselves  
 35 cause a significant increase in hematocrit, but they acquire  
 that property once they are derivatized suitably with  
 polyethylene glycol polymers. They are therefore useful

- 8 -

industrially as starting materials for preparing other compositions of the present invention.

The invention further provides isolated nucleic acids encoding the analogs of Formula I as well as vectors and  
5 host cells comprising these nucleic acids. The invention also encompasses a transgenic or chimeric non-human animal or plant, comprising host cells capable of expressing the EPO analogs of Formula I.

In another aspect, the invention provides  
10 erythropoietic compounds having a protein portion and a polymer portion, wherein the protein portion is selected from the group consisting of: non-glycosylated human erythropoietin and non-glycosylated erythropoietin analogs and wherein the polymer portion consists of from 1 to 5  
15 polymer chains of the formula:  $[R-O-(CH_2CH_2-O)_X-(CH_2)_Y-NH]$ , wherein R is H or  $C_1$  to  $C_4$  alkyl, X is a number from about 70 to about 1200, and Y is a number from 1 to 4; and the polymer chain is covalently bonded to the protein portion by a secondary amine bond, or a pharmaceutically-acceptable  
20 salt thereof.

The invention further provides a method for preparing polymer-derivatized, non-glycosylated erythropoietic compounds, comprising: a) adding a polyethylene glycol-aldehyde polymer to a solution containing non-glycosylated  
25 erythropoietin under conditions that permit the formation of an imine bond between an amino group of the protein and the aldehyde group of the polymer; and b) adding a reducing agent to reduce the imine bond to a secondary amine bond.

The invention also provides a method for increasing the  
30 hematocrit level in a mammal comprising administering a therapeutically effective amount of a polymer-derivatized, non-glycosylated erythropoietic compound to the mammal.

Because the modified analogs of the present invention do not have attached carbohydrate groups, they are less

- 9 -

likely to be cleared from the circulation by natural glycosylation-mediated routes. Addition of polyethylene polymers to several different proteins has been shown to improve their pharmaceutical properties. Yet, there are  
5 very few polymer-modified proteins that have been approved as therapeutics. Addition of polyethylene glycol groups to proteins has been problematic in that the coupling/activation step can cause substantial loss of biological activity. In addition, the inability to control  
10 the coupling reaction has resulted in the addition of polymers at positions which cause steric hindrance and preclusion of protein-receptor binding.

The present invention, however, provides polyethylene glycol derivatized non-glycosylated EPO analogs which show  
15 stability and bioactivity *in vivo*. Because the carbohydrate chains attached to EPO have been shown to affect the protein's stability, solubility, and *in vivo* activity, it is surprising that stable non-glycosylated EPO analogs can be produced and modified to exhibit improved therapeutic  
20 qualities.

Moreover, the modification of the positively charged residues on non-glycosylated EPO (NGE) and NGE analogs to produce a longer-acting therapeutic is problematic and non-trivial in light of the proposed interactions between ligand  
25 and receptor. It has been proposed that EPO receptor specificity is mediated through the positively charged (basic) residues on rHuEPO interacting with the negatively charged (acidic) residues on the EPO receptor. [S. Elliott, et al., (1997) Mapping the active site of recombinant human erythropoietin, *Blood* 89:493-502]. Consequently, the  
30 finding that modification of the positively-charged residues on EPO and EPO analogs enhances *in vivo* activity is counter-intuitive, surprising, and unexpected.

- 10 -

Figure 1: Expression vector for NGE and NGEA.

Figure 2: Blood concentrations of immunoreactive substances in mice following a single subcutaneous or intravenous dose (1 µg/kg) of either MR-NGE-166Δ or a commercial glycosylated EPO.

Figure 3: (A) Preparative size exclusion chromatogram (SEC) of the reaction mixture from a synthesis of PEG (5 kDa)-aldehyde/MR-NGE-24K, 38K, 83K, 126K, 166Δ. The pooled fractions are designated by letter. (B) Analytical HPLC size exclusion chromatogram of the pooled fractions.

Figure 4: Preparative size exclusion chromatogram (SEC) of the reaction mixture from a synthesis of PEG (20 kDa)-aldehyde/MR-NGE-24K, 38K, 83K, 126K, 166Δ. The pooled fractions are designated by letter. (B) Analytical HPLC size exclusion chromatogram of the pooled fractions.

Figure 5: SDS-PAGE analysis of final pooled products (see Figures 3 and 4).

Figure 6: Matrix-Assisted Laser Desorption Ionization-Time of Flight Mass Spectrometry (MALDI-TOF-MS) analysis of pooled fractions: (A) Compound B; (B) Compound C; (C) Compound D; (D) MR-NGE-24K, 38K, 83K, 126K.

Figure 7: MALDI-TOF-MS analysis of pooled fractions: (A) Compound F; (B) Compound G.

Figure 8: Lys\_C enzymatic digest of a 20 kDa mono-PEGylated-MR-NGE-166Δ (Compound Z) (Example 1e) and MR-NGE-166Δ.

Figure 9: Relationship between the degree of PEGylation with either 5 kDa PEG (Panel A) or 20 kDa PEG (Panel B) and in vitro activity.

Figure 10: In vivo activity as a function of degree of PEGylation and size of PEG moieties. Delta is the difference in hematocrit from baseline.

Figure 11: Inverse correlation between in vitro and in vivo activities as a function of dose. Delta is the



- 11 -

difference in hematocrit from baseline. The value at  
log[specific activity U/mg] = 5.22 and Delta(day7-day0 =  
-1.4 was estimated using the measured in vitro activity of  
MR-NGE-166A and the measured in vivo activity of PBS/BSA  
5 control.

Figure 12: In vivo activity of compound injected as a  
function of degree of 20kDa pegylation. Delta is the  
difference between hematocrit from baseline.

Figure 13: In vivo activity comparison between  
10 experimental compounds and control at 7, 10, and 14 days  
after a single subcutaneous 50 µg/kg dose.

Figure 14: Pharmacokinetic profiles of Compound C  
(Panel A) and Compound G (Panel B) in Fischer 344 male rats  
given a single dose (10 µg/kg) intravenously (solid markers)  
15 or subcutaneously (open markers).

For purposes of the present invention, as disclosed and  
claimed herein, the following terms and abbreviations are  
defined below. The terms and abbreviations used in this  
20 document have their normal meanings unless otherwise  
designated. For example, "°C" refers to degrees Celsius;  
"mmol" refers to millimole or millimoles; "mg" refers to  
milligrams; "µg" refers to micrograms; "ml or mL" refers to  
milliliters; and "µl or µL" refers to microliters.

25 Amino acids abbreviations are as set forth in 37 C.F.R.  
§ 1.822 (b) (2) (1994).

"Erythropoietin" means human erythropoietin, and is  
abbreviated herein as "EPO" or "huEPO." EPO is a  
glycoprotein hormone that is secreted by the human kidney,  
30 that is found in human blood, and that stimulates formation  
of erythrocytes (erythropoiesis) in human bone marrow. The  
amino acid sequence of the predominant allelic variant of  
the protein portion of erythropoietin is known. EPO  
consists of 166 amino acids, is comprised of about 40%

- 12 -

carbohydrate, by mass, and has a total molecular weight of approximately 30.4 kDa. The carbohydrate structure of EPO is heterogeneous, whereas the amino acid sequence of the predominant human allelic variant is not. Therefore, these  
5 terms refer to a heterogeneous group of EPO or huEPO molecules.

"Non-glycosylated erythropoietin" means human erythropoietin lacking attached glycosyl chains, and is abbreviated "NGE." NGE has the amino acid sequence of EPO,  
10 but lacks N-linked glycosyl chains at positions 24, 38, and 83 and the O-linked glycosyl chain at position 126 (SEQ ID NO:4). In addition, NGE may lack the amino acid at position 166 or may have an Arg at position 166.

Non-glycosylated EPO can be conveniently expressed in  
15 cell types that lack the ability to post-translationally attach glycosyl moieties to a protein, or can be produced by enzymatically removing the glycosyl chains from EPO.

"Erythropoietin analog" means a glycosylated protein having nearly the same amino acid sequence as EPO, and  
20 having the ability to increase hematocrit when properly administered to a mammal, but differing from EPO in having one or more amino acid modifications. An amino acid modification may be an insertion, a deletion, a replacement, or an inversion of one or more amino acids. Glycosylated  
25 EPO Analogs are abbreviated "GEA."

"Non-glycosylated erythropoietin analog" means a non-glycosylated erythropoietin having nearly the same amino acid sequence as EPO, but differing in amino sequence from EPO in having one or more amino acid modifications. Non-  
30 glycosylated erythropoietin analog is abbreviated "NGEA." NGEAs includes non-glycosylated EPO that has the amino acid at position 166 deleted. In addition, NGEAs include EPO wherein the amino acid at position 166 is any amino acid.

- 13 -

"NGE-166Δ" represents a non-glycosylated protein having the same sequence as NGE, wherein Arg at position 166 is deleted.

5 "NGE-24E,38E,83E,88E,126E" and "NGE[5E]" represent a non-glycosylated protein having the same sequence as NGE, except Asn at positions 24, 38, and 83, Trp at 88, and Ser at 126 are replaced with Glu, and the Arg at position 166 is absent, present, or is any other amino acid. "NGE-24E,38E,83E,88E,126E,166Δ" and "NGE[5E]166Δ" have the same  
10 sequence as "NGE-24E,38E,83E,88E,126E" and "NGE[5E]" wherein Arg at position 166 is deleted. NGE[5E] and NGE[5E]166Δ are NGEAs.

"MR-NGE" represents a non-glycosylated protein having the same sequence as NGE, except that it has a Met-Arg  
15 leader sequence and the Arg at position 166 is absent, present, or is any other amino acid. MR-NGE-166Δ has the same sequence as MR-NGE wherein Arg at position 166 is deleted. MR-NGE and MR-NGE-166Δ are NGEAs.

"MR-NGE-88E" represents a non-glycosylated protein  
20 having the same sequence as NGE, except that it has a Met-Arg leader sequence, Trp at 88 is replaced with Glu, and Arg at 166 is absent, present, or is any other amino acid. "MR-NGE-88E,166Δ" has the same sequence as "MR-NGE-88E" wherein Arg at position 166 is deleted. MR-NGE-88E and MR-NGE-  
25 88E,166Δ are NGEAs.

"MR-NGE-88K" represents a non-glycosylated protein having the same sequence as NGE, except that it has a Met-Arg leader sequence, Trp at 88 is replaced with Lys, and Arg  
30 at position 166 is absent, present, or is any other amino acid. MR-NGE-88K,166Δ has the same sequence as MR-NGE-88K wherein Arg at position 166 is deleted. MR-NGE-88K and MR-NGE-88K,166Δ are NGEAs.

"MR-NGE-88P" represents a non-glycosylated protein having the same sequence as NGE, except that it has a Met-

- 14 -

Arg leader sequence, Trp at 88 is replaced with Pro, and Arg at position 166 is absent, present, or is any other amino acid. "MR-NGE-88P,166Δ" has the same sequence as MR-NGE-88P wherein Arg at position 166 is deleted. MR-NGE-88P and MR-NGE-88P,166Δ are NGEAs.

"MR-NGE-88S" represents a non-glycosylated protein having the same sequence as NGE, except that it has a Met-Arg leader sequence, Trp at 88 is replaced with Ser, and Arg at 166 is absent, present, or is any other amino acid. "MR-NGE-88S,166Δ" has the same sequence as MR-NGE-88S wherein Arg at position 166 is deleted. MR-NGE-88S and MR-NGE-88S,166Δ are NGEAs.

"MR-NGE-76E,88E,139E,154E" and "MR-NGE[4E]" represent a non-glycosylated protein having the same sequence as NGE, except that it has a Met-Arg leader sequence, Arg at 76, Trp at 88, Arg at 139, and Lys at 154 are replaced with Glu, and Arg at position 166 is absent, present, or is any other amino acid. "MR-NGE-76E,88E,139E,154E,166Δ" and "MR-NGE[4E]166Δ" have the same amino acid sequence as MR-NGE-76E,88E,139E,154E and MR-NGE[4E] wherein Arg at position 166 is deleted. MR-NGE[4E] and MR-NGE[4E]166Δ are NGEAs.

"MR-NGE-24E,38E,83E,88E,126E" or "MR-NGE[5E]" represents a non-glycosylated protein having the same sequence as NGE, except that it has a Met-Arg leader sequence, Asn at 24, 38, and 83, Trp at 88, and Ser at 126 are replaced with Glu, and Arg at position 166 is absent, present, or is any other amino acid. "MR-NGE-24E,38E,83E,88E,126E,166Δ" or "MR-NGE[5E]166Δ" have the same sequence as MR-NGE-24E,38E,83E,88E,126E or MR-NGE[5E] wherein Arg at position 166 is deleted. MR-NGE[5E] and MR-NGE[5E]166Δ are NGEAs.

"MR-NGE-24K,38K,83K,88K,126K,166Δ" or "MR-NGE[5K]" represents a non-glycosylated protein having the same sequence as NGE, except that it has a Met-Arg leader

- 15 -

sequence, Asn at 24, 38, and 83, Trp at 88, and Ser at 126 are replaced with Lys, and Arg at position 166 is absent, present, or is any other amino acid. "MR-NGE-24K,38K,83K,88K,126K,166Δ" or "MR-NGE[5K]166Δ" have the same  
5 sequence as MR-NGE-24K,38K,83K,88K,126K or MR-NGE[5K] wherein Arg at position 166 is deleted. MR-NGE[5K] and MR-NGE[5K]166Δ are NGEAs.

"MR-NGE-24E,38E,83E,126E" or "MR-NGE[W5E]" represents a non-glycosylated protein having the same sequence as NGE,  
10 except that it has a Met-Arg leader sequence, Asn at 24, 38, and 83 and Ser at 126 are replaced with Glu, and Arg at position 166 is absent, present, or is any other amino acid. "MR-NGE-24E,38E,83E,126E,166Δ" or "MR-NGE[W5E]166Δ" have the same amino acid sequence as "MR-NGE-24E,38E,83E,126E" or  
15 "MR-NGE[W5E]" wherein Arg at position 166 is deleted. MR-NGE[W5E] and MR-NGE[W5E]166Δ are NGEAs.

"MR-NGE-24K,38K,83K,126K" or "MR-NGE[W5K]" represents a non-glycosylated protein having the same sequence as NGE, except that it has a Met-Arg leader sequence, Asn at 24, 38,  
20 and 83 and Ser at 126 are replaced with Lys, and Arg at position 166 is absent, present or is any other amino acid. "MR-NGE-24K,38K,83K,126K,166Δ" or "MR-NGE[W5K]166Δ" have the same sequence as MR-NGE-24K,38K,83K,126K or MR-NGE[W5K] wherein Arg at position 166 is deleted. MR-NGE[W5K] and MR-  
25 NGE[W5K]166Δ are NGEAs.

- 16 -

Table I includes a list of NGEA compounds prepared using the cloning, expression, and purification methods described herein. Single letters represent the amino acids at particular positions in Formula I.

5

Abbreviation for NGEA	Amino acids at variable positions in Formula I										
	-2	-1	24	38	76	83	88	126	139	154	166
NGE-166Δ	-	-	N	N	R	N	W	S	R	K	-
NGE- 24E, 38E, 83E, 88E, 126E, 166Δ or NGE[5E]166Δ	-	-	E	E	R	E	E	E	R	K	-
MR-NGE-166Δ	M	R	N	N	R	N	W	S	R	K	-
MR-NGE-88E, 166Δ	M	R	N	N	R	N	E	S	R	K	-
MR-NGE-88K, 166Δ	M	R	N	N	R	N	K	S	R	K	-
MR-NGE-88P, 166Δ	M	R	N	N	R	N	P	S	R	K	-
MR-NGE-88S, 166Δ	M	R	N	N	R	N	S	S	R	K	-
MR-NGE- 76E, 88E, 139E, 154E, 166Δ or MR-NGE[4E]166Δ	M	R	N	N	E	N	E	S	E	E	-
MR-NGE- 24E, 38E, 83E, 88E, 126E, 166Δ or MR-NGE[5E]166Δ	M	R	E	E	R	E	E	E	R	K	-
MR-NGE- 24K, 38K, 83K, 88K, 126K, 166Δ or MR-NGE[5K]166Δ	M	R	K	K	R	K	K	K	R	K	-
MR-NGE- 24E, 38E, 83E, 126E, 166Δ or MR-NGE[W5E]166Δ	M	R	E	E	R	E	W	E	R	K	-
MR-NGE- 24K, 38K, 83K, 126K, 166Δ or MR-NGE[W5K]166Δ	M	R	K	K	R	K	W	K	R	K	-

"Erythropoietic activity" refers to the ability of a compound to stimulate erythropoiesis. Erythropoietic activity can be assessed *in vitro*, as well as *in vivo*.


- 10 Erythropoietic activity generally refers to the ability of a compound to cause an increase in hematocrit levels from an established baseline when administered by an acceptable route of administration at effective doses. *In vitro*

- 17 -

activity can be determined by the method outlined in Example 4 and *in vivo* activity can be determined by the method outlined in Example 5.

"Erythropoietic compound" refers to a non-glycosylated, polymer-derivatized protein having erythropoietic activity

"Polyethylene glycol" or "PEG" refers to a hydrophilic polymer having the formula:




wherein, x is a number from about 70 to about 1200, preferably from about 450 to about 1200, even more preferably from about 450 to about 700.

"PEG-aldehyde" refers to a hydrophilic polymer having the formula:



wherein Y is number from 1 to 4, and x is a number from about 70 to about 1200, preferably from about 450 to about 1200, even more preferably from about 450 to about 700.

"PEG-Propionaldehyde" refers to a PEG-aldehyde hydrophilic polymer having the formula:



wherein, x is a number from about 70 to about 1200, preferably from about 450 to about 1200, even more preferably from about 450 to about 700.

"PEGylated protein" refers to a protein having 1 to 5 polymer chains of the formula:  $[\text{R-O}-(\text{CH}_2\text{CH}_2\text{-O})_x-(\text{CH}_2)_Y\text{-NH}]$ , wherein R is H or  $\text{C}_1$  to  $\text{C}_4$  alkyl, X is a number from about 70 to about 1200, preferably from about 450 to about 1200, and even more preferably from about 450 to about 700, and Y is a number from 1 to 4; and the polymer chain is covalently bonded to the protein by a secondary amine bond.

"PEGylated NGE" refers to a non-glycosylated EPO as described above with 1 to 5 polymer chains of the formula:  $[\text{R-O}-(\text{CH}_2\text{CH}_2\text{-O})_x-(\text{CH}_2)_Y\text{-NH}]$ , wherein R is H or  $\text{C}_1$  to  $\text{C}_4$  alkyl, X is a number from about 70 to about 1200, preferably

- 18 -

from about 225 to about 1200, even more preferably from about 340 to about 1200, even more preferably from about 450 to about 1200, and even more preferably from about 450 to about 700, and Y is a number from 1 to 4; and the polymer  
5 chain is covalently bonded to the protein by a secondary amine bond.

"PEGylated NGEA" refers to a non-glycosylated EPO analog as described above with 1 to 5 polymer chains of the formula:  $[R-O-(CH_2CH_2-O)_X-(CH_2)_Y-NH]$ , wherein R is H or  $C_1$  to  
10  $C_4$  alkyl, X is a number from about 70 to about 1200, preferably from about 225 to about 1200, even more preferably from about 340 to about 1200, even more preferably from about 450 to about 1200, and even more preferably from about 450 to about 700, and Y is a number  
15 from 1 to 4; and the polymer chain is covalently bonded to the protein by a secondary amine bond.

"Mono-PEGylated NGEA" refers to a non-glycosylated EPO analog covalently attached to a single polymer chains of the formula:  $[R-O-(CH_2CH_2-O)_X-(CH_2)_Y-NH]$ , wherein R is H or  $C_1$  to  
20  $C_4$  alkyl, X is a number from about 70 to about 1200, preferably from about 225 to about 1200, even more preferably from about 340 to about 1200, even more preferably from about 450 to about 1200, and even more preferably from about 450 to about 700, and Y is a number  
25 from 1 to 4; and the polymer chain is covalently bonded to the protein by a secondary amine bond.

"Di-PEGylated NGEA" refers to a non-glycosylated EPO analog covalently attached to two polymer chains of the formula:  $[R-O-(CH_2CH_2-O)_X-(CH_2)_Y-NH]$ , wherein R is H or  $C_1$  to  
30  $C_4$  alkyl, X is a number from about 70 to about 1200, preferably from about 225 to about 1200, even more preferably from about 340 to about 1200, even more preferably from about 450 to about 1200, and even more preferably from about 450 to about 700, and Y is a number



- 19 -

from 1 to 4; and the polymer chain is covalently bonded to the protein by a secondary amine bond.

"Tri-PEGylated NGEA" refers to a non-glycosylated EPO analog covalently attached to three polymer chains of the  
5 formula:  $[R-O-(CH_2CH_2-O)_X-(CH_2)_Y-NH]$ , wherein R is H or  $C_1$  to  $C_4$  alkyl, X is a number from about 70 to about 1200, preferably from about 225 to about 1200, even more preferably from about 340 to about 1200, even more preferably from about 450 to about 1200, and even more  
10 preferably from about 450 to about 700, and Y is a number from 1 to 4; and the polymer chain is covalently bonded to the protein by a secondary amine bond.

"Tetra-PEGylated NGEA" refers to a non-glycosylated EPO analog covalently attached to four polymer chains of the  
15 formula:  $[R-O-(CH_2CH_2-O)_X-(CH_2)_Y-NH]$ , wherein R is H or  $C_1$  to  $C_4$  alkyl, X is a number from about 70 to about 1200, preferably from about 225 to about 1200, even more preferably from about 340 to about 1200, even more preferably from about 450 to about 1200, and even more  
20 preferably from about 450 to about 700, and Y is a number from 1 to 4; and the polymer chain is covalently bonded to the protein by a secondary amine bond.

"Multi-PEGylated NGEA" refers to a non-glycosylated EPO analog covalently attached to four or more polymer chains of  
25 the formula:  $[R-O-(CH_2CH_2-O)_X-(CH_2)_Y-NH]$ , wherein R is H or  $C_1$  to  $C_4$  alkyl, X is a number from about 70 to about 1200, preferably from about 225 to about 1200, even more preferably from about 340 to about 1200, even more preferably from about 450 to about 1200, and even more  
30 preferably from about 450 to about 700, and Y is a number from 1 to 4; and the polymer chain is covalently bonded to the protein by a secondary amine bond.

- 20 -

"Lys\_C" refers to an endoprotease with specificity for cleaving peptides and proteins C-terminal to lysine residues.

All nucleic acid sequences, unless otherwise designated, are written in the direction from the 5' end to the 3' end, frequently referred to as "5' to 3'."

All amino acid or protein sequences, unless otherwise designated, are written commencing with the amino-terminus ("N-terminus") and concluding with the carboxy-terminus ("C-terminus").

"Base pair" or "bp" as used herein refers to DNA or RNA. The abbreviations A,C,G, and T correspond to the 5'-monophosphate forms of the deoxyribonucleosides (deoxy)adenosine, (deoxy)cytidine, (deoxy)guanosine, and thymidine, respectively, when they occur in DNA molecules. The abbreviations U,C,G, and A correspond to the 5'-monophosphate forms of the ribonucleosides uridine, cytidine, guanosine, and adenosine, respectively when they occur in RNA molecules. In double stranded DNA, base pair may refer to a partnership of A with T or C with G. In a DNA/RNA, heteroduplex base pair may refer to a partnership of A with U or C with G. (See the definition of "complementary", infra.)

"Digestion" or "Restriction" of DNA refers to the catalytic cleavage of the DNA with a restriction enzyme that acts only at certain sequences in the DNA ("sequence-specific endonucleases"). The various restriction enzymes used herein are commercially available and their reaction conditions, cofactors, and other requirements were used as would be known to one of ordinary skill in the art. Appropriate buffers and substrate amounts for particular restriction enzymes are specified by the manufacturer or can be readily found in the literature.

- 21 -

"Ligation" refers to the process of forming phosphodiester bonds between two double stranded nucleic acid fragments. Unless otherwise provided, ligation may be accomplished using known buffers and conditions with a DNA  
5 ligase, such as T4 DNA ligase.

"Plasmid" refers to an extrachromosomal (usually) self-replicating genetic element. Plasmids are generally designated by a lower case "p" followed by letters and/or numbers. The starting plasmids herein are either  
10 commercially available, publicly available on an unrestricted basis, or can be constructed from available plasmids in accordance with published procedures. In addition, equivalent plasmids to those described are known in the art and will be apparent to the ordinarily skilled  
15 artisan.

"Recombinant DNA cloning vector" as used herein refers to any autonomously replicating agent, including, but not limited to, plasmids and phages, comprising a DNA molecule to which one or more additional DNA segments can or have  
20 been added.

"Recombinant DNA expression vector" as used herein refers to any recombinant DNA cloning vector in which a promoter to control transcription of the inserted DNA has been incorporated.

25 "Transcription" refers to the process whereby information contained in a nucleotide sequence of DNA is transferred to a complementary RNA sequence.

"Transfection" refers to the uptake of an expression vector by a host cell whether or not any coding sequences  
30 are, in fact, expressed. Numerous methods of transfection are known to the ordinarily skilled artisan, for example, calcium phosphate co-precipitation, and electroporation. Successful transfection is generally recognized when any

- 22 -

indication of the operation of this vector occurs within the host cell.

"Transformation" refers to the introduction of DNA into an organism so that the DNA is replicable, either as an  
5 extrachromosomal element or by chromosomal integration. Methods of transforming bacterial and eukaryotic hosts are well known in the art, many of which methods, such as nuclear injection, protoplast fusion or by calcium treatment using calcium chloride are summarized in J. Sambrook, et  
10 al., *Molecular Cloning: A Laboratory Manual*, (1989). Generally, when introducing DNA into Yeast the term transformation is used as opposed to the term transfection.

"Translation" as used herein refers to the process whereby the genetic information of messenger RNA (mRNA) is  
15 used to specify and direct the synthesis of a polypeptide chain.

"Vector" refers to a nucleic acid compound used for the transfection and/or transformation of cells in gene manipulation bearing polynucleotide sequences corresponding  
20 to appropriate protein molecules which, when combined with appropriate control sequences, confers specific properties on the host cell to be transfected and/or transformed. Plasmids, viruses, and bacteriophages are suitable vectors. Artificial vectors are constructed by cutting and joining  
25 DNA molecules from different sources using restriction enzymes and ligases. The term "vector" as used herein includes Recombinant DNA cloning vectors and Recombinant DNA expression vectors.

"Complementary" or "Complementarity", as used herein,  
30 refers to pairs of bases (purines and pyrimidines) that associate through hydrogen bonding in a double stranded nucleic acid. The following base pairs are complementary: guanine and cytosine; adenine and thymine; and adenine and uracil.

- 23 -

"Hybridization" as used herein refers to a process in which a strand of nucleic acid joins with a complementary strand through base pairing. The conditions employed in the hybridization of two non-identical, but very similar, complementary nucleic acids varies with the degree of complementarity of the two strands and the length of the strands. Such techniques and conditions are well known to practitioners in this field.

"Isolated amino acid sequence" refers to any amino acid sequence, however, constructed or synthesized, which is locationally distinct from the naturally occurring sequence.

"Isolated DNA compound" refers to any DNA sequence, however constructed or synthesized, which is locationally distinct from its natural location in genomic DNA.

"Isolated nucleic acid compound" refers to any RNA or DNA sequence, however constructed or synthesized, which is locationally distinct from its natural location.

"Primer" refers to a nucleic acid fragment which functions as an initiating substrate for enzymatic or synthetic elongation.

"Promoter" refers to a DNA sequence which directs transcription of DNA to RNA.

"Probe" refers to a nucleic acid compound or a fragment, thereof, which hybridizes with another nucleic acid compound.

"Stringency" refers to a set of hybridization conditions which may be varied in order to vary the degree of nucleic acid affinity for other nucleic acids.

"PCR" refers to the widely-known polymerase chain reaction employing a thermally-stable DNA polymerase.

"Leader sequence" refers to an N-terminal sequence of amino acids which can be enzymatically or chemically removed to produce the desired polypeptide of interest.

- 24 -

"Secretion signal sequence" refers to a sequence of amino acids generally present at the N-terminal region of a larger polypeptide functioning to initiate association of that polypeptide with the cell membrane and secretion of that polypeptide through the cell membrane.

This invention provides derivatives of non-glycosylated EPO and non-glycosylated EPO analogs which have improved therapeutic properties compared to glycosylated EPO proteins. The NGE and NGEA derivatives of the present invention are produced by expression in a recombinant system followed by modification with polyethylene glycol (PEG).

Non-derivitized non-glycosylated EPO proteins of the present invention do not have practical *in vivo* activity. [Lin, et al., US Patent 4,703,008; K. Yamaguchi, et al., (1991) Effects of site-directed removal of N-glycosylation sites in human erythropoietin on its production and biological properties, *J. of Biol. Chem.* 266:20434-20439]. However, PEGylation of non-glycosylated EPO and certain non-glycosylated EPO analogs imparts properties such as increased plasma half-life, reduced immunogenicity and antigenicity, improved solubility, reduced proteolytic susceptibility, improved bioavailability, reduced toxicity, reduced affinity to serum binding proteins, improved thermal and mechanical stability, as well as, improved compatibility with depot formulations compared to glycosylated erythropoietin and NGE.

Thus, it is an object of the present invention to produce polymer derivatized non-glycosylated erythropoietic compounds with improved properties compared with EPO, and thereby avoiding the perceived problems associated with increasing the carbohydrate content of EPO. These problems include reduce bioavailability and unfavorable pharmacokinetics.

- 25 -

Preparation of NGE and NGEAs:

The compounds of the present invention may be produced by a variety of methods including recombinant DNA technology or well known chemical procedures, such as solution or  
5 solid-phase peptide synthesis, or semi-synthesis in solution beginning with protein fragments coupled through conventional solution methods.

Vectors and Host Cells:

10 The present invention also relates to vectors that include isolated nucleic acid molecules, host cells that are genetically engineered with the recombinant vectors, and the production of NGE or NGEAs by recombinant techniques.

The nucleotides encoding the proteins of the present  
15 invention can optionally be joined to a vector containing a selectable marker for propagation in a host. Generally, with respect to mammalian cell hosts, a plasmid vector is introduced in a precipitate, such as a calcium phosphate precipitate, or in a complex with a charged lipid, or by  
20 other methods that are well known to those with ordinary skill in the art. If the vector is a viral vector, it can be introduced directly into mammalian host cells or introduced using viral supernatant produced by packaging *in vitro* using an appropriate packaging cell line. Bacterial  
25 viral vectors (bacteriophages) can also be packaged *in vitro* using packaging cell extracts commercially available and then transfected into host bacterial cells.

The DNA insert should be operatively linked to an appropriate promoter, such as the phage lambda PL promoter, the *E. coli* *lac*, *trp* and *tac* promoters, the SV40 early and  
30 late promoters and promoters of retroviral LTRs, as well as the glyceraldehyde phosphate dehydrogenase (GAPDH) and alcohol oxidase (AOX) promoters to name a few. Other suitable promoters will be known to the skilled artisan.

- 26 -

The expression constructs will further contain sites for transcription initiation, termination and, in the transcribed region, a ribosome binding site for translation. The coding portion of the mature transcripts expressed by

5 the constructs will preferably include a translation initiating at the beginning and a termination codon (e.g., UAA, UGA or UAG) appropriately positioned at the end of the mRNA to be translated.

Expression vectors will preferably include at least one

10 selectable marker. Such markers include, e.g., dihydrofolate reductase or neomycin resistance for mammalian cell culture, neomycin resistance or complementation of auxotrophic markers for yeasts, and tetracycline, ampicillin, kanamycin, or chloramphenicol resistance genes

15 for culturing in *E. coli* and other bacteria. Representative examples of appropriate hosts include, but are not limited to, bacterial cells, such as *E. coli*, *Streptomyces* and *Salmonella typhimurium* cells; fungal cells, such as *Aspergillus niger*; yeast cells, such as *Pichia pastoris* and

20 *Saccharomyces cerevisiae*; insect cells such as *Drosophila* S2 and *Spodoptera* Sf9 cells; animal cells such as CHO, COS, AV-12, HEK293, and Bowes melanoma cells; and plant cells such as tobacco, corn, and soybean. Appropriate culture mediums and conditions for the above-described host cells are known

25 in the art. Vectors preferred for use in bacteria include pQE70, pQE60 and pQE-9, available from Qiagen; pBS vectors, Phagescript vectors, Bluescript vectors, pNH8A, pNH16a, pNH18A, pNH46A, available from Stratagene; pET30 vectors from Novagen, and ptrc99a, pKK223-3, pKK233-3, pDR540, pRIT5

30 available from Pharmacia. Preferred eucaryotic vectors include pWLNEO, pSV2CAT, pOG44, pXT1 and pSG available from Stratagene; pCDNA3, pRCrSV, and pRCMV from Invitrogen, Inc.; and pSVK3, pBPV, pMSG and pSVL available from Pharmacia. Preferred vectors for expression in *Pichia*



- 27 -

pastoris include the pPIC vectors commercially available from Invitrogen, Inc. Other suitable vectors will be readily apparent to the skilled artisan.

Introduction of a vector construct into a host cell can be effected by calcium phosphate transfection, DEAE-dextran mediated transfection, cationic lipid-mediated transfection, electroporation, transduction, infection, transformation or other methods. Such methods are described in many standard laboratory manuals, such as Ausubel, et al., ed., *Current Protocols in Molecular Biology*, Greene Publishing, NY, NY (1987-1998) and Sambrook, et al., *Molecular Cloning: A Laboratory Manual*, 2<sup>nd</sup> Edition, Cold Spring Harbor, NY (1989).

The proteins of the present invention can be expressed in a modified form, such as a fusion protein, and can include not only secretion signals, but also additional heterologous functional regions. For instance, a region of additional amino acids can be added to the N-terminus of an analog to improve stability and persistence in the host cell, during purification, or during subsequent handling and storage. Also, peptide moieties can be added to facilitate purification. Such regions can be removed prior to final preparation of an active protein. Such methods are described in many standard laboratory manuals, such as Sambrook, supra, Chapters 17.29-17.42 and 18.1-18.74; Ausubel, supra, Chapters 16, 17 and 18.

Specifically, a gene encoding MR-NGE-166Δ was constructed synthetically by *in vitro* hybridization using a set of six overlapping oligonucleotides from the positive strand of human erythropoietin cDNA with six complementary oligonucleotides (negative strand). The codon usage for the synthetic MR-NGE-166Δ gene was 100% optimized for *E. coli* codon usage (Wisconsin Package, v.8) while maintaining a low GC content at the 5' end. The hybridized oligonucleotides

- 28 -

were ligated with T4 DNA ligase and the ligation product amplified by PCR using Pfu turbo DNA polymerase (Stratagene).

PCR introduced two restriction endonuclease cleavage sites into the synthetic MR-NGE-166 $\Delta$  gene, a 5' NdeI site and a 3' BamHI site. The MR-NGE-166 $\Delta$  PCR product was then cloned into the NdeI and BamH I sites in the commercial expression vector pET30a (Novagen) to create pET30a\_MR-NGE-166 $\Delta$  (Figure 1). Protein expression was carried out using the commercial expression strain BL21(DE3) (Novagen). Genes encoding non-glycosylated erythropoietin analogs were prepared by introducing point mutations at different positions using PCR according to the procedures described by Nelson, R., M., and Long, G., L., (1989), *Anal. Biochem.* 180:147-151.

#### *Expression of Proteins in Host Cells*

Using nucleic acids of the present invention, one may express a protein of the present invention in a recombinantly engineered cell, such as bacteria, yeast, insect, or mammalian cells. The cells produce the protein in a non-natural condition (e.g., in quantity, composition, location, and/or time), because they have been genetically altered through human intervention to do so.

It is expected that those of skill in the art are knowledgeable in the numerous expression systems available for expression of a nucleic acid encoding a protein of the present invention. No attempt to describe in detail the various methods known for the expression of proteins in prokaryotes or eukaryotes will be made.

In brief summary, the expression of isolated nucleic acids encoding a protein of the present invention will typically be achieved by operably linking, for example, the DNA or cDNA to a promoter (which is either constitutive or

- 29 -

inducible), followed by incorporation into an expression vector. The vectors can be suitable for replication and integration in either prokaryotes or eukaryotes. Typical expression vectors contain transcription and translation  
5 terminators, initiation sequences and promoters useful for regulation of the expression of the DNA encoding a protein of the present invention. To obtain high level expression of a cloned gene, it is desirable to construct expression vectors which contain, at the minimum, a strong promoter to direct  
10 transcription, a ribosome binding site for translational initiation, and a transcription/translation terminator.

Alternatively, nucleic acids of the present invention may be fused downstream of inducible promoters. Gene expression is then induced by exposing a host cell containing  
15 the gene of interest fused downstream of the inducible promoter to a specific transcriptional inducer. Such methods are well known in the art, e.g., as described in US patent Nos. 5,580,734, 5,641,670, 5,733,746, and 5,733,761, entirely incorporated herein by reference.

20

#### *Expression in Prokaryotes*

Prokaryotic cells may be used as hosts for expression. Prokaryotes most frequently are represented by various strains of *E. coli*; however, other microbial strains may also  
25 be used. Commonly used prokaryotic control sequences which are defined herein to include promoters for transcription initiation, optionally with an operator, along with ribosome binding site sequences, include such commonly used promoters as the beta lactamase (penicillinase) and lactose (lac)  
30 promoter systems (Chang, et al., *Nature* 198:1056 (1977)), the tryptophan (trp) promoter system (Goeddel, et al., *Nucleic Acids Res.* 8:4057 (1980)), the bacteriophage T7 promoter and RNA polymerase, and the bacteriophage lambda derived P L promoter and N-gene ribosome binding site (Shimatake, et al.,

- 30 -

Nature 292:128 (1981)). The inclusion of selection markers in DNA vectors transfected in *E. coli* is also useful. Examples of such markers include genes specifying resistance to ampicillin, tetracycline, kanamycin, or chloramphenicol.

5       The vector is selected to allow introduction into the appropriate host cell. Bacterial vectors are typically of plasmid or phage origin. Appropriate bacterial cells are infected with phage vector particles or transfected with naked phage vector DNA. If a plasmid vector is used, the  
10 bacterial cells are transformed with the plasmid vector DNA. Expression systems for expressing a protein of the present invention are also available using *Bacillus subtilis* and *Salmonella* (Palva, et al., Gene 22:229-235 (1983); Mosbach, et al., Nature 302:543-545 (1983)).

15       For example, pET30a\_MR-NGE-166A was transfected into the commercial expression strain, BL21(DE3) (Novagen) (Figure 1). Log phase cells were typically grown at 37°C to OD<sub>600</sub> = 0.9 and induced to express MR-NGE-166A with 1 mM IPTG and harvested 3 hours post-induction. The above  
20 fermentation conditions resulted in high expression levels of MR-NGE-166A (> 100 mg/L) that accumulated in inclusion bodies.

#### Expression in Eukaryotes

25       A variety of eukaryotic expression systems such as yeast, insect cell lines, plant and mammalian cells, are known to those of skill in the art. As explained briefly below, a nucleic acid of the present invention can be expressed in these eukaryotic systems.

30       Synthesis of heterologous proteins in yeast is well known. F. Sherman, et al., Methods in Yeast Genetics, Cold Spring Harbor Laboratory (1982) is a well-recognized work describing the various methods available to produce the protein in yeast. Two widely utilized yeast systems for

- 31 -

production of eukaryotic proteins are *Saccharomyces cerevisiae* and *Pichia pastoris*. Vectors, strains, and protocols for expression in *Saccharomyces* and *Pichia* are known in the art and available from commercial suppliers (e.g., Invitrogen). Suitable vectors usually have expression control sequences, such as promoters, including 3-phosphoglycerate kinase or alcohol oxidase, and an origin of replication, termination sequences and the like as desired.

The sequences encoding proteins of the present invention can also be ligated to various expression vectors for use in transfecting cell cultures of, for instance, mammalian, insect, or plant origin. Illustrative of cell cultures useful for the production of the peptides are mammalian cells. Mammalian cell systems often will be in the form of monolayers of cells although mammalian cell suspensions may also be used. A number of suitable host cell lines capable of expressing intact proteins have been developed in the art, and include the HEK293, BHK21, AV-12, and CHO cell lines. Expression vectors for these cells can include expression control sequences, such as an origin of replication, a promoter (e.g., the CMV promoter, a HSV tk promoter or pgk (phosphoglycerate kinase) promoter), an enhancer (Queen, et al., *Immunol. Rev.* 89:49 (1986)), and processing information sites, such as ribosome binding sites, RNA splice sites, polyadenylation sites (e.g., SV40 large T Ag poly A addition site or Bovine growth hormone poly A addition site), and transcriptional terminator sequences. Other animal cells useful for production of proteins of the present invention are available, for instance, from the American Type Culture Collection Catalogue of Cell Lines and Hybridomas (7th edition, 1992).

Appropriate vectors for expressing proteins of the present invention in insect cells are usually derived from the SF9 baculovirus. Suitable insect cell lines include

- 32 -

mosquito larvae, silkworm, armyworm, moth and *Drosophila* cell lines such as a Schneider cell line (See Schneider, J. *Embryol. Exp. Morphol.* 27:353-365 (1987)).

As with yeast, when higher animal or plant host cells are employed, polyadenylation or transcription terminator sequences are typically incorporated into the vector. An example of a terminator sequence is the polyadenylation sequence from the bovine growth hormone gene. Sequences for accurate splicing of the transcript may also be included. An example of a splicing sequence is the VP1 intron from SV40 (Sprague, et al., *J. Virol.* 45:773-781 (1983)). Additionally, gene sequences to control replication in the host cell may be incorporated into the vector such as those found in bovine papilloma virus type-vectors. M. Saveria-Campo, *Bovine Papilloma Virus DNA, a Eukaryotic Cloning Vector in DNA Cloning Vol. II, a Practical Approach*, D. M. Glover, Ed., IRL Press, Arlington, VA, pp. 213-238 (1985).

#### *Signal Peptides:*

Signal peptides may be used to facilitate the extracellular discharge of proteins in both prokaryotic and eukaryotic environments. It has been shown that the addition of a heterologous signal peptide to a normally cytosolic protein may result in the extracellular transport of the normally cytosolic protein. Alternate signal peptide sequences may function with heterologous coding sequences.

Signal peptides, such as the 27 amino acid human EPO secretion signal sequence, the alpha factor peptide or the human serum albumin signal peptide can be incorporated into the modified EPO proteins of the present invention to facilitate extracellular translocation or intracellular destination.

- 33 -

*Leader Sequences:*

The present invention contemplates leader sequences having a variable sequence of amino acids fused to the N-terminus of the mature protein. The leader sequence is preferably exposed to the solvent which enables it to be cleaved by DAP or other aminopeptidases, e.g., the cathepsins. A leader sequence consisting of amino acids which will facilitate exposure of the leader to the solvent and allow for subsequent removal by DAP is preferred. A preferred leader sequence will contain an even number from two to twenty hydrophilic amino acids which can be cleaved by a specific enzyme such as a serine protease or a DAP enzyme. A more preferred leader sequence is the sequence Met-Arg fused to the N-terminal amino acid of the NGEAs of the present invention (see Table I).

*Protein Folding:*

Once an expression vector carrying a gene encoding a NGE or NGEA of the present invention is transfected into a suitable host cell using standard methods, cells that contain the vector are propagated under conditions suitable for expression of the recombinant analog protein. For example, if the recombinant gene has been placed under the control of an inducible promoter, suitable growth conditions would incorporate the appropriate inducer. The recombinantly produced protein may be purified from cellular extracts of transformed cells by any suitable means. Preferably, the *E. coli*-derived inclusion bodies are solubilized using a denaturing solution, preferably containing urea or guanadine hydrochloride, and protein initially purified by cation or anion exchange chromatography, depending on the pI of the protein being purified. Preferably, the eluted protein can be refolded by exhaustive dialysis against a renaturing solution or by

- 34 -

infinite dilution which involves dripping the protein containing solution into a renaturing buffer. The refolded protein can then be concentrated using either a tangential flow filtration system with a S3Y10 spiral cartridge, Amicon  
5 Flow through concentrator, or PEG-induced dehydration in a dialysis bag.

*Protein Purification:*

NGE and NGEAs of the present invention can be purified  
10 from recombinant cell cultures by well-known methods including ammonium sulfate or ethanol precipitation, acid extraction, anion or cation exchange chromatography, phosphocellulose chromatography, hydrophobic interaction chromatography, affinity chromatography, reversed-phase  
15 chromatography, hydroxylapatite chromatography, and size exclusion chromatography. Most preferably, anion or cation exchange chromatography, phosphocellulose chromatography and size exclusion chromatography are used.

Additionally, the non-glycosylated EPO proteins of the  
20 present invention may be fused at the N-terminal or C-terminal end to several histidine residues. This "histidine-tag" enables a single-step protein purification method referred to as "immobilized metal ion affinity chromatography" (IMAC), essentially as described in U.S.  
25 Patent 4,569,794, which hereby is incorporated by reference. The IMAC method enables rapid isolation of substantially pure protein starting from a crude extract of cells that express a recombinant protein, as described above.

30 *Cleavage of Leader Sequences:*

Following expression of non-glycosylated EPO proteins containing N-terminal leader sequences in bacteria, yeast, or higher eukaryotic cells, the proteins can be digested with an aminopeptidase such as a mono- or di-aminopeptidase,



- 35 -

a serine protease such as trypsin, or even by chemical cleavage such as cleavage by cyanogen bromide. Watson, et al., (1976) *Methods Microb.* 9:1-14 describe different aminopeptidases present in different bacteria including *E. coli* and is entirely herein incorporated by reference.

Dipeptidylaminopeptidases (DAPs) are enzymes which hydrolyze the penultimate amino terminal peptide bond releasing dipeptides from the unblocked amino-termini of peptides and proteins. There are currently four classes of dipeptidylaminopeptidases (designated DAP-I, DAP-II, DAP-III and DAP-IV) that differ based on their physical characteristics and the rates at which they react with their substrates. DAP-I is a relatively non-specific DAP that catalyzes the release of many dipeptide combinations from the unblocked amino termini of peptides and proteins. DAP-I shows little or no activity if the emergent dipeptide is Pro-X, or X-Pro (where X is any amino acid). DAP-II shows a preference for amino terminal dipeptide sequences that begin with Arg-X or Lys-X, and to a lesser extent, X-Pro. DAP-II exhibits significantly lower reaction rates versus most other dipeptide combinations. DAP-III appears to have a propensity toward amino terminal dipeptide sequences of the form Arg-Arg and Lys-Lys. DAP-IV shows its highest rate of hydrolytic activity toward dipeptide sequences of the form X-Pro. The DAP enzymes, particularly DAP-I and DAP-IV, have been shown to be useful in processing proteins.

Processing of precursor polypeptides containing leader sequences by bovine dipeptidylaminopeptidase is disclosed in Becker et al., United States Patent 5,126,249 and is herein incorporated by reference. One particular DAP commonly used to process precursor polypeptides is that derived from the slime mold *Dictyostelium discoideum*. The synthesis, purification and use of this protease, often abbreviated as dDAP, are described in European Patent Publication 595,476,

- 36 -

published May 4, 1994, and United States Patent Applications 08/301,519, filed September 7, 1994, and 08/445,308, filed May 19, 1995, all of which are herein incorporated by reference.

5       The dDAP reaction is generally conducted in an aqueous medium suitably buffered to obtain and maintain a pH from about 2.0 to about 6.5. Preferably, the pH of the medium ranges from about 3.0 to about 4.5, and most preferably, from about 3.0 to about 3.5. The dDAP reaction, however,  
10       may be conducted at a pH higher than 6.5 in the presence of urea.

Characterization of non-glycosylated EPO analogs:

      The development of non-glycosylated proteins having in  
15       vivo erythropoietic activity has been difficult due to the limited solubility and stability of the proteins in the absence of their native carbohydrate chains. [Owers-Narhi, et al., (1991) The effect of carbohydrate on the structure and stability of erythropoietin, *J. Biol. Chem.* 266:23022-  
20       23026]. The NGEs and NGEAs of the present invention, however, have been successfully cloned, expressed in *E. coli* inclusion bodies, refolded, and purified.

      NGE and NGEAs generally have in vitro activity that is comparable to glycosylated human EPO. Yet, as discussed  
25       briefly above, NGE and NGEAs do not have any detectable in vivo activity, i.e., no increase in hematocrit was observed, in 6 week old B6C3F1 mice dosed at 0.2 µg/mouse/injection with 4 injections/day, for two weeks. This lack of in vivo activity is likely due to the rapid clearance of the  
30       molecule. The rapid clearance is hypothesized to be associated with either receptor-based and/or renal clearance mechanisms. However, surface partitioning to cell surface glucosaminoglycans or binding to circulating binding-proteins cannot be excluded. Rapid clearance of non-

- 37 -

glycosylated EPO was demonstrated by the 150-fold reduction in plasma levels observed within 30 minutes after an intravenous dose of a NGEA (e.g. MR-NGE-166Δ) (Figure 2). The subcutaneous dose showed analogous reduction in plasma levels (Figure 2).

Thus, whether a particular compound stimulates *in vivo* erythropoiesis cannot be accurately predicted based solely on its *in vitro* activity. NGE and NGEAs are highly active *in vitro*, yet show minimal or no *in vivo* activity. In addition, PEGylated EPO analog species can have reduced *in vitro* activity, yet have enhanced *in vivo* activity. *In vitro* activity, however, is useful as a general indicator of the ability of the molecule to bind to the receptor and induce a response. Thus, *in vitro* activity provides some information regarding whether a particular mutation will have positive or negative effects on activity. Many NGEA derivatives, such as mono- and di-PEGylated NGEAs, have *in vitro* activities similar to a commercial GEA. However, these molecules exhibit varying degrees of *in vivo* activity compared with a commercial GEA.

Furthermore, the pharmacokinetic results show that the size of the polymer is critical for bioavailability. Surprisingly, a NGEA derivatized with 20 kDa PEG had greater subcutaneous bioavailability than one derivatized with 5 kDa PEG. This was highly unexpected.

Physical stability is also essential for therapeutic formulations. The physical stability of NGE and NGEA depends on their conformational stability, charge residues at one or more of the glycosylation sites, ionic strength, pH, protein concentration, and glycerol concentration, among other possible factors. MR-NGE[5E], MR-NGE[5K], MR-NGE[W5E], and MR-NGE[W5K] have similar or improved conformational and physical stability relative to NGE at

- 38 -

0.1 mg/mL protein in 20 mM TRIS, 0.5 M NaCl, 1 mM EDTA, pH 7.4, 37°C as measured in unfolding studies by circular dichroism and aggregation studies by 90° light scattering measurements, respectively. It has been also identified  
5 that the physical stability of these proteins can be modulated by ionic strength and glycerol. Surprisingly, the non-glycosylated EPO analogs of the present invention show enhanced physical stability at NaCl ranging from 150mM to 1 M. Furthermore, the physical stability of proteins were  
10 enhanced with increasing amounts of glycerol, 0-35%. The improved solubility and physical stability of these non-glycosylated molecules are beneficial during their purification and derivatization.

Stability studies indicate that point mutations at  
15 position 88 alone have a deleterious effect on physical stability regardless of the charge introduced at this site. However, this reduction in physical stability can be mitigated by the introduction of negative or positive charges at the glycosylation sites. Physical stability and  
20 conformational studies indicate that improved stability in these analogs is due to a convolution of effects that include conformational stability and surface charge affects. However, it should be recognized that physically unstable agonists created by single point mutations at position 88  
25 can be derivatized to create molecules that exhibit the *in vivo* activity and physical stability needed for a practical therapeutic.

30 PEGylation of non-glycosylated EPO and non-glycosylated EPO analogs:

Once the non-glycosylated EPO proteins of the present invention are appropriately expressed, refolded (depending on the expression system used), and purified, they can be modified. Proteins can be modified by covalently linking

- 39 -

synthetic or natural macromolecules to the surface of the proteins. However, it has been difficult to endow delicate proteins with suitable new properties by attaching polymers without causing any loss of their functionality.

5       The present invention provides specific NGE and NGEA derivatives which are modified by polyethylene glycol. A wide variety of methods have been developed to produce proteins modified by polyethylene glycol (PEG). PEGylation  
10 of proteins can overcome many of the pharmacological and toxicological problems associated with using proteins as therapeutics. However, for any individual protein it is uncertain whether modification by polyalkylene groups will cause significant losses in bioactivity.

      The bioactivity of polymer modified proteins can be  
15 effected by factors such as: i) the size of the polymer; ii) the particular sites of attachment; iii) the degree of modification; iv) adverse coupling conditions; v) whether a linker is used for attachment or whether the polymer is directly attached; vi) generation of harmful co-products;  
20 vii) damage inflicted by the activated polymer; or viii) retention of charge. Depending on the coupling reaction used, polymer modification of cytokines, in particular, has resulted in dramatic reductions in bioactivity. Francis, G.E., et al., (1998) PEGylation of cytokines and other  
25 therapeutic proteins and peptides: the importance of biological optimization of coupling techniques, *Intl. J. Hem.* 68:1-18.

      The present invention provides non-glycosylated EPO and non-glycosylated EPO analogs with polyethylene glycol  
30 polymers covalently attached, thereto. The methods of this invention are used to directly attach polymers which vary in size. Furthermore, the addition of polymers is controlled such that a bioactive population of NGE protein derivatives can be purified for therapeutic use.

- 40 -

There are numerous methods of covalently attaching polyalkylene polymers to proteins. For example, Inada, et al., describe a method using cyanuric chloride, 2,4,6-trichloro-s-triazine, and monomethoxypolyethylene glycol.

- 5 Inada, et al., (1986) Engineering physicochemical and biological properties of protein by chemical modification, Trends, Biotech. March:68-73. The preferred method for preparing the NGE protein derivatives of the present invention, however, involves the use of Polyethylene glycol-  
10 propionaldehyde (PEG-propionaldehyde) or polyethylene glycol-acetaldehyde (PEG-acetaldehyde) to directly attach ethylene glycol groups to amino groups. The amino groups include the N-terminus and lysine residues.

- The PEGylation process of the present invention  
15 utilizes a stable linker-less aldehyde modification process, via reductive alkylation. This method minimizes immunogenic responses associated with the presence of a linker. Use of a PEG-aldehyde such as PEG-propionaldehyde or PEG-acetaldehyde results in the formation of an imine through  
20 any of the primary amines present on the protein. This imine is then reduced with sodium cyanoborohydride or sodium borohydride to convert the imine to a secondary amine.

- It is preferable that the procedure use a molar excess of PEG-aldehyde, relative to the number of amines present on  
25 the protein. A preferred ratio is 0.08 to 24 and a more preferred ratio is 1 to 10. The reactions are preferably performed between a pH 7.0 to 9.0 at 4°C for 15 to 40 hours. However, lower pH values are recognized to restrict labeling to the N-terminus (pH 5.0 to 7.0) and higher pH are  
30 recognized to enhance ε-amino group labeling on lysine residues (pH 9.0 to 10.0). Specific conditions required for PEGylation of non-glycosylated EPO and EPO analogs are set forth in Example 1.

- 41 -

PEGylation may be performed using PEG-aldehydes with the following formula:  $[R-O-(CH_2CH_2-O)_X-(CH_2)_Y-NH]$ , wherein R is H or C<sub>1</sub> to C<sub>4</sub> alkyl, X is a number from about 70 to about 1200, preferably about 450 to about 1200, and even more  
5    preferrably about 450 to about 700, and Y is a number from 1 to 4.

The PEGylation reactions were run under conditions that permit the formation of an imine bond. Specifically, the pH of the solution ranged from 7 to 9 and methoxy-PEG-  
10    propionaldehyde concentrations ranged from 1 to 24 molar excess of the amine concentration. The PEGylation reactions were normally run at 4°C to minimize degradation of the protein by other chemical and physical degradation processes. The different non-glycosylated EPO derivatives  
15    were isolated using size exclusion chromatography (SEC) (Figures 3 and 4).

#### Characterization of PEGylated Non-glycosylated EPO Analogs

For illustrative purposes, the characterization of  
20    PEGylated MR-NGE-[W5K]-166Δ and MR-NGE-166Δ with either PEG(5 kDa)-aldehyde or PEG (20 kDa)-aldehyde is discussed (Example 3). MR-NGE-[W5K]-166Δ and MR-NGE-166Δ contain 13 and 9 primary amines, respectively. Consequently, the PEGylation of these compounds with either the 5 kDa or 20  
25    kDa methoxy-PEG-propionaldehyde polymer (PEG (5 kDa)-aldehyde and PEG (20 kDa)-aldehyde, respectively) yield a variety of modified species that exhibit both *in vivo* and *in vitro* activity.

Species, PEGylated to varying degrees, were separated  
30    and enriched based on differences in hydrodynamic size. These pools were characterized using analytical HPLC-SEC, SDS-PAGE, and MALDI-Tof Mass Spectrometry. For example, the 5 kDa PEG modification of MR-NGE[W5K]-166Δ yielded three distinct pools with increasing degrees of PEGylation. Each

- 42 -

distinct characterized pool was designated with a letter. The Compound B pool consisted of a mixture of primarily 5 kDa Tri- and Tetra-PEGylated species. The Compound C pool consisted of primarily 5 kDa Di-PEGylated species and the  
5 Compound D pool consisted of primarily 5 kDa Mono-PEGylated species. Compound E was unmodified MR-NGE[W5K]-166A.

The PEG (20 kDa) modification of MR-NGE[W5K]-166A yielded several distinct pools with increasing degrees of PEGylation. The Compound F pool consisted of primarily 20  
10 kDa PEGylated species (greater than Di-Pegylated) and the Compound G pool consisted of a blend of 20 kDa Mono-, Di-, and Tri-PEGylated species. In addition, the PEG (20 kDa) modification of MR-NGE-166A also yielded several distinct pools with increasing degrees of PEGylation. For example,  
15 Compound AH was isolated from a reaction mixture and consisted of primarily 20 kDa Tri-Pegylated species.

The degree of PEGylation and site of PEGylation can be controlled to primarily the N-terminus by lowering the pH and reducing the PEG:amine ratio. Reactions run at pH 7 and  
20 a 1.5:1 molar ratio of PEG-aldehyde:amine groups, preferentially react with the N-terminal  $\alpha$ -amino group (Example 1g). This is illustrated by a Lys\_C enzymatic digestion of the Compound Z pool which consists of primarily a 20 kDa Mono-PEGylated MR-NGE-166A species (Example 3).  
25 The Lys\_C enzymatic digestion of Compound Z indicated that only the N-terminal peptide, liberated by the digestion, had a modified retention time.

*Activity of PEGylated non-glycosylated EPO analogs:*

30 These various PEGylated species were also tested for in vitro activity using a <sup>3</sup>H-thymidine uptake assay in spleen cells (see Example 4). Mono-PEGylation with 5 kDa PEG generally has only a minor impact on in vitro activity; however, each subsequent 5 kDa PEG addition (e.g. di-, tri-,



- 43 -

and tetra-PEGylation) results in a 0.55 ( $\pm$  0.04) log reduction in *in vitro* activity (Figure 9A). The impact of adding 20 kDa PEG moieties on *in vitro* activity is even greater, i.e., 0.63 ( $\pm$  0.09) log reduction in *in vitro* activity per 20 kDa PEG moiety attached (Figure 9B).

Non-glycosylated PEGylated EPO analog derivatives were also tested for *in vivo* activity. *In vivo* results were monitored by assaying hematocrit levels in 5-8 week old B6C3F1 or CD-1 mice injected with various PEGylated species given at a single dose of either 10, 20, 50, or 100  $\mu$ g/mouse/injection (Figures 10, 12, and 13; Tables V-VII; Example 5). The results clearly show, for dose 20  $\mu$ g/kg, an increase in hematocrit relative to the PBS/BSA control. For comparison purposes, glycosylated EPO was also ran.

The results indicate that the PEGylated non-glycosylated samples have sufficient plasma half-lives to elicit a hematopoietic response unlike non-glycosylated EPO which showed no response due to rapid clearance from the plasma (Figure 2). In addition, a comparison of *in vivo* activity at 7, 10, and 14 days following a single dose of a 20kDa tri-PEGylated NGE (Compound AM), glycosylated EPO, or PBS show that only the tri-PEGylated NGE illicit a response beyond 7 days indicating that this compound has an increased half-life relative to wild type glycosylated EPO (Figure 13).

Furthermore, the degree of PEGylation and the size of the PEG moiety have an effect on *in vivo* activity. Generally, the greater the degree of PEGylation and/or the larger the size of the PEG entities the greater the *in vivo* activity (Figure 10, Table V). Optimal *in vivo* activity was observed with PEG moieties > 5 kDa in size (Table V) and proteins modified with an average of ~ 3 PEG moieties (Figure 12).

- 44 -

It is important to note that the *in vitro* and *in vivo* activities of the PEGylated proteins are inversely correlated (Figure 11). The compounds with lower *in vitro* activity have higher *in vivo* activity. The data presented  
5 in support of the present invention suggests that the mere measurement of an *in vitro* activity is not necessarily predictive of performance *in vivo*.

Interestingly, estimates of bioavailability of Compounds C and G representing PEGylated pools of MR-  
10 NGE[WSK]-166Δ (discussed above) relative to non-glycosylated MR-NGE-166Δ (Figure 2) are 4.5% and 60%, respectively (Figure 14, Table VIII). These results are surprisingly counter-intuitive, based on the hydrodynamic size of the two compounds. By SEC on TSK3000 column, Compound C has a main  
15 peak retention time that is similar to that observed with ~121 kDa molecular weight protein and Compound G has a main peak retention time that is similar to that observed with ~466 kDa molecular weight protein. Consequently, if the bioavailability is presumed to be primarily constrained by  
20 the hydrodynamic size of the protein, the bioavailability of C would have been expected to exceed that of Compound G. Thus, the bioavailability of these PEGylated compounds is being controlled by something other than hydrodynamic size. Clearly the results indicate that 20 kDa PEGylated species  
25 of non-glycosylated erythropoietin would be preferred over 5 kDa PEG modifications because of the extended plasma half-life and improved bioavailability (Figure 14; Table VIII).

Thus, PEGylation can replace glycosylation as a means of extending plasma half-life by reducing the clearance rate  
30 of the non-glycosylated erythropoietin. Furthermore, the plasma half-life of the PEGylated species is greater than that which is achievable through natural glycosylation, due in part, to PEGylated species of EPO not being susceptible

- 45 -

to the clearance mechanisms associated with the carbohydrate structures.

*Solubility and Stability of non-glycosylated EPO analog*  
5 *derivatives:*

The present invention provides not only modified proteins with erythropoietin activity that have a longer time-action but EPO analogs which have improved solubility and/or stability properties which may be especially useful  
10 for alternate delivery methodologies and formulation development. Thus, the pharmaceutical properties of the modified EPO analogs of the present invention make it possible to develop formulations that are more convenient and efficacious for the patient.

15 For example, the physical stability of Compound Z, which is characterized as consisting of primarily a 20 kDa mono-PEGylated MR-NGE-166Δ species was studied under stabilizing high ionic strength conditions (20mM TRIS, 500mM NaCl, 1mM EDTA, pH 7.4), physiologic ionic strength  
20 conditions (20mM TRIS, 150mM NaCl, 1mM EDTA, pH 7.4), and "multi-use formulation" conditions (20mM TRIS, 150mM NaCl, 1mM EDTA, 3.0 mg/mL m-cresol, pH 7.4). These studies indicated that the addition of a single 20 kDa PEG moiety at the N-terminus significantly improves the physical stability  
25 of non-glycosylated EPO (see Example 3, Table III)).

The present invention thus, provides non-glycosylated variants of erythropoietin modified to have improved biophysical properties. PEGylation can replace  
30 glycosylation as a means of extending plasma half-life by reducing the clearance rate of the non-glycosylated erythropoietin. This time extension is greater than that which is achievable through natural glycosylation, since the PEGylated species of proteins are not susceptible to the

- 46 -

clearance mechanisms associated with the carbohydrate structures. Preferably, 20 kDa PEG-modified NGEAs are favored because of the greater extension of plasma half-life and, surprisingly, increased bioavailability. In addition, 5 the derivatized analogs of the present invention provide improved solubility and/or stability making them useful in a manufacturing environment. Lastly, the discoveries associated with the present invention make it possible to develop formulations that are more convenient and 10 efficacious for the patient. Moreover, the utilization of an *E. coli*-derived source as opposed to mammalian cell-derived source would reduce the cost of manufacturing and reduce the cost of the product to the consumer.

The following examples are presented to further 15 describe the present invention. The scope of the present invention is not to be construed as merely consisting of the following examples. Those skilled in the art will recognize that the particular reagents, equipment, and procedures described are merely illustrative and are not intended to 20 limit the present invention in any manner.

#### Example 1: PEGylation of EPO analogs

PEG-propionaldehyde modification of non-glycosylated EPO and EPO analogs:

25 EPO analogs were reacted with 5 kDa and 20 kDa polyethylene glycol-aldehydes (PEG-aldehydes) to produce analogs covalently attached to ethylene groups. The PEGylated analogs were then separated into populations based on the extent of PEGylation and then various populations 30 were tested to determine *in vivo* and *in vitro* activity. One skilled in the art would understand that the exemplified compounds can be made with or without an amino acid present at position 166.

- 47 -

1a: MR-NGE[W5K]-166Δ covalently attached to 5 kDa PEGs:

A 1.75 mL aliquot of a 2.36 mg/mL solution of MR-NGE[W5K]-166Δ was used to dissolve 35.70 mg of methoxy-PEG(5kDa)-aldehyde (Lot# PT-037-36, purchased from Shearwater Polymers, Inc. Huntsville, Alabama) (4.3:1 ratio of PEG:NH<sub>2</sub> groups). A 100 uL solution of 7.5 mg/mL NaCNBH<sub>3</sub> was added to reductively alkylate the Schiff's base that was generated upon the reaction of the aldehyde with the primary amine. The reaction was performed in 50 mM Borate, 150 mM NaCl, pH 9.0, at 4°C, for ~40 hours. PEGylated species were then purified, characterized, and tested for activity (see Examples below).

1b: MR-NGE[W5K]-166Δ covalently attached to 20 kDa PEGs:

A 1.75 mL aliquot of a 2.36 mg/mL solution of MR-NGE[W5K]-166Δ was used to dissolve 134.6 mg of methoxy-PEG (20 kDa)-aldehyde (Lot#PT-087-01, purchased from Shearwater Polymers, Inc., Huntsville, Alabama) (4.1:1 ratio of PEG:NH<sub>2</sub> groups). A 100 uL solution containing 7.5 mg/mL of NaCNBH<sub>3</sub> was added to reductively alkylate the Schiff's base that was generated upon the reaction of the aldehyde with the primary amine. The reaction was performed at in 50 mM Borate, 150 mM NaCl, pH 9.0, at 4°C, for ~40 hours. PEGylated species were then purified, characterized, and tested for activity (see Examples below).

1c: MR-NGE-166Δ covalently attached to 20 kDa PEGs:

A 3.7 mL aliquot of a 1.6 mg/mL solution of MR-NGE-166Δ was used to dissolve 86.3 mg of methoxy-PEG (20 kDa)-aldehyde (1.5:1 ratio of PEG:NH<sub>2</sub> groups). A 36.2 uL solution containing 7.5 mg/mL of NaCNBH<sub>3</sub> was added to reductively alkylate the Schiff's base that was generated upon the reaction of the aldehyde with the primary amine. The reaction was performed at in Phosphate Buffered Saline,

- 48 -

pH 7.0, at 4°C, for ~40 hours. PEGylated products were purified and characterized as described below.

1d: MR-NGE-166Δ covalently attached to 5 kDa PEGs:

A 7.4 mL aliquot of a 0.94 mg/mL solution of MR-NGE-  
5 166Δ was used to dissolve 236.6 mg of methoxy-PEG (5kDa)-  
aldehyde (14:1 ratio of PEG:NH<sub>2</sub> groups). A 396.4 uL  
solution containing 7.5 mg/mL of NaCNBH<sub>3</sub> was added to  
reductively alkylate the Schiff's base that was generated  
upon the reaction of the aldehyde with the primary amine.  
10 The reaction was performed at in 50 mM Borate, Phosphate  
Buffered Saline, pH 9.0, at 4°C, for approximately 40 hours.

1e: MR-NGE-166Δ covalently attached to 20 kDa PEGs:

A 0.25 mL aliquot of a 0.5 mg/mL solution of MR-NGE-  
166Δ was used to dissolve 1.6 mg of methoxy-PEG (20 kDa)-  
15 aldehyde (1.3:1 ratio of PEG:NH<sub>2</sub> groups). A 0.7 uL aliquot  
of a 7.5 mg/mL solution of NaCNBH<sub>3</sub> was added to reductively  
alkylate the Schiff's base that was generated upon the  
reaction of the aldehyde with the primary amine. The  
reaction was performed at pH 9.0, at 4°C, for approximately  
20 40 hours.

1f: MR-NGE-166Δ covalently attached to 20 kDa PEGs:

A 0.25 mL aliquot of a 1.54 mg/mL solution of MR-NGE-  
166Δ was used to dissolve 25.3 mg of methoxy-PEG (20kDa)-  
aldehyde (6.8:1 ratio of PEG:NH<sub>2</sub> groups). A 10.6 uL aliquot  
25 of a 7.5 mg/mL solution of NaCNBH<sub>3</sub> was added to reductively  
alkylate the Schiff's base that was generated upon the  
reaction of the aldehyde with the primary amine. The  
reaction was performed at pH 9.0, at 4°C, for approximately  
40 hours.

30 1g: MR-NGE-166Δ covalently attached to 20 kDa PEGs:

A 0.25 mL aliquot of a 1.72 mg/mL solution of MR-NGE-  
166Δ was used to dissolve 6.1 mg of methoxy-PEG (20 kDa)-  
aldehyde (1.5:1 ratio of PEG:NH<sub>2</sub> groups). A 2.6 uL aliquot  
of a 7.5 mg/mL solution of NaCNBH<sub>3</sub> was added to reductively

- 49 -

alkylate the Schiff's base that was generated upon the reaction of the aldehyde with the primary amine. The reaction was performed at pH 7.0, at 4°C, for approximately 40 hours.

5        1h: MR-NGE-166Δ covalently attached to 20 kDa PEGs:

A 0.25 mL aliquot of a 0.5 mg/mL solution of MR-NGE-166Δ was used to dissolve 4.8 mg of methoxy-PEG (20 kDa)-aldehyde (4:1 ratio of PEG:NH<sub>2</sub> groups). A 2.0 uL aliquot of a 7.5 mg/mL solution of NaCNBH<sub>3</sub> was added to reductively  
10 alkylate the Schiff's base that was generated upon the reaction of the aldehyde with the primary amine. The reaction was performed at pH 7.0, at 4°C, for approximately 40 hours.

1j: MR-NGE-166Δ covalently attached to 20 kDa PEGs:

15        A 0.25 mL aliquot of a 1.33 mg/mL solution of Met-Arg-EPO was used to dissolve 9.2mg of methoxy-PEG (20K)-aldehyde (3.6:1 ratio of PEG:NH<sub>2</sub> groups). A 3.9 uL aliquot of a 7.5 mg/mL solution of NaCNBH<sub>3</sub> was added to reductively alkylate the Schiff's base that was generated upon the reaction of  
20 the aldehyde with the primary amine. The reaction was performed at pH 8.0, at 4°C, for approximately 40 hours.

1k: MR-NGE-166Δ covalently attached to 20 kDa PEGs:

A 0.25 mL aliquot of a 1.33 mg/mL solution of MR-NGE-166Δ was used to dissolve 9.4mg of methoxy-PEG (20 kDa)-  
25 aldehyde (2.9:1 ratio of PEG:NH<sub>2</sub> groups). A 3.9 uL aliquot of a 7.5 mg/mL solution of NaCNBH<sub>3</sub> was added to reductively alkylate the Schiff's base that was generated upon the reaction of the aldehyde with the primary amine. The reaction was performed at pH 8.0, at 4°C, for approximately  
30 40 hours.

1l: MR-NGE-166Δ covlalently attached to 5 kDa PEGs:

A 1.8 mL aliquot of a 1.07 mg/mL solution of MR-NGE-166Δ was used to dissolve 4.7 mg of methoxy-PEG(5kDa)-aldehyde, 1:1 ratio of PEG:NH<sub>2</sub> groups, 7.8 uL of a 7.5 mg/mL

- 50 -

solution of NaCNBH<sub>3</sub> was added to reductively alkylate the Schiff's base that was generated upon the reaction of the aldehyde with the primary amine. The reaction was performed in PBS at pH 7.0, 4C, for ~90 hours.

- 5           1m: MR-NGE[W5E]-166Δ covalently attached to 5 kDa  
PEGs:

A 1.8 mL aliquot of a 1.27 mg/mL solution of MR-NGE[W5E]-166Δ was used to dissolve 5.7 mg of methoxy-PEG(5kDa)-aldehyde, 1:1 ratio of PEG:NH<sub>2</sub> groups, 9.3 uL of a  
10 7.5 mg/mL solution of NaCNBH<sub>3</sub> was added to reductively alkylate the Schiff's base that was generated upon the reaction of the aldehyde with the primary amine. The reaction was performed in PBS at pH 7.0, 4C, for ~90 hours.

- 15           1n: MR-NGE[W5K]-166Δ covalently attached to 5 kDa  
PEGs:

A 1.8 mL aliquot of a 0.82 mg/mL solution of MR-NGE[W5K]-166Δ was used to dissolve 3.7 mg of methoxy-PEG(5kDa)-aldehyde, 0.7:1 ratio of PEG:NH<sub>2</sub> groups, 6.0 uL of  
20 a 7.5 mg/mL solution of NaCNBH<sub>3</sub> was added to reductively alkylate the Schiff's base that was generated upon the reaction of the aldehyde with the primary amine. The reaction was performed in PBS at pH 7.0, 4C, for ~90 hours.

- 1o: MR-NGE[W5E]-166Δ covalently attached to 20 kDa  
PEGs:

25           A 1.8 mL aliquot of a 1.27 mg/mL solution MR-NGE[W5E]-166Δ was used to dissolve 22.2 mg of methoxy-PEG(20kDa)-aldehyde, 1:1 ratio of PEG:NH<sub>2</sub> groups, 9.3 uL of a 7.5 mg/mL solution of NaCNBH<sub>3</sub> was added to reductively alkylate the Schiff's base that was generated upon the reaction of the  
30 aldehyde with the primary amine. The reaction was performed in PBS at pH 7.0, 4C, for ~90 hours.



- 51 -

1p: MR-NGE[W5K]-166Δ covalently attached to 20 kDa  
PEGs:

A 1.8 mL aliquot of a 0.82 mg/mL solution of MR-  
5 NGE[W5K]-166Δ was used to dissolve 14.2 mg of methoxy-  
PEG(5kDa)-aldehyde, 0.6:1 ratio of PEG:NH<sub>2</sub> groups, 6.0 uL of  
a 7.5 mg/mL solution of NaCNBH<sub>3</sub> was added to reductively  
alkylate the Schiff's base that was generated upon the  
reaction of the aldehyde with the primary amine. The  
10 reaction was performed in PBS at pH 7.0, 4C, for ~90 hours.

1q: MR-NGE-166Δ covalently attached to 20 kDa PEGs:

A 2.8 mL aliquot of a 0.87 mg/mL solution of MR-NGE-  
166Δ was used to dissolve 36.7 mg of methoxyl-PEG(20kDa)-SPA  
(N-hydroxysuccinimidyl ester of methoxypoly(ethylene glycol))  
15 propionic acid, MW 20000; Shearwater Polymers) in seven  
equal aliquots over 2.5 hours at 4C. This represents a  
1.5:1 ratio of PEG:NH<sub>2</sub> groups. The reaction was performed  
in PBS at pH 7.0, 4C, for ~19 hours. The material was  
purified by hydrophobic interaction chromatography on a TSK  
20 phenyl-5PW column (7.5mm x 7.5cm) using a mobile phase  
consisting of 25mM sodium phosphate and decreasing salt  
gradient of ammonium sulfate (loaded at 700mM ammonium  
sulfate, pH 7.2). The collected material was further  
purified by size exclusion chromatography on a TSK 3000  
25 column. The material eluting with the largest size was  
pooled and labeled as compound AH.

Example 2 Purification and Folding  
of Non-glycosylated EPO and EPO analogs

30 Following induction with IPTG, 4 liter bacterial  
cultures containing host cells transformed with PET30\_NGE  
constructs were spun down to obtain a bacterial pellet.  
This bacterial pellet was re-suspended in 180 mL of 50 mM  
Tris/HCl pH 8.0. To the resuspended pellet, 80 mg of

- 52 -

Lysozyme (Boehringer Mannheim, Lot number 84093121), 0.9 mL of 1M MgCl<sub>2</sub>, 80 µL of DNase I (1 mg/mL in 20 mM Tris, 50 mM NaCl, 50 % glycerol, pH 7.4) were added. This mixture was stirred at RT for 30 minutes and then sonicated for 8 minutes with 5 second on pulse and 2 second off pulse at settings of 100% tune and 65% amplitude in a Cole Parma Ultrasonic Homogenizer. The lysed material was spun down at 13,000 rpm in a Sorvall rotor for 20 minutes. The pellets were re-suspended in 120 mL of 0.1% Triton X-100, 5 mM EDTA using a PowerGen 700 Homogenizer from Fisher Scientific. The material was spun down at 13,000 rpm in a Sorvall rotor for 20 minutes. The pellets were re-suspended in 60 mL of 0.1% Triton X-100, 5 mM EDTA and 60 mL of 0.5 M KCl and then spun down at 13,000 rpm as stated before. The pellets were then washed with 120 mL of distilled H<sub>2</sub>O and centrifuged at 13,000 rpm in a Sorvall rotor. These purified inclusion bodies were either used immediately or frozen at -20°C.

Inclusion bodies from 2 liters of induced bacterial culture were used as the starting material. These inclusion bodies were solubilized in 150 mL of 10 mM Tris, 5 mM cysteine, 7M urea, pH 7.0. Many mutants were soluble in these conditions. However, if a mutant remained cloudy under these conditions, the pH of the solubilization mixture was adjusted to pH 9 or 10 for 30 min then readjusted the pH to between 7.0 and 7.4. This first step in the purification was achieved using a Waters 650E Advanced Protein Purification System. This material was then placed on either 180 mL column of Q Sepharose Fast Flow resin or SP Sepharose Fast Flow resin (Pharmacia) depending on the pI of the protein which was being purified. The ion exchange column was equilibrated in 10 mM Tris, 5 mM cysteine, 7M urea, pH 7.0. The flow rate was 10 mL/min. The protein was eluted from the column using a linear gradient from 0 to 1 M NaCl over 55 minutes. The protein elution was monitored by

- 53 -

UV absorbance at 280 nm. Fraction containing the protein of interest were pooled for refolding.

Refolding of non-glycosylated EPO analogs was successfully achieved by two different methods. The first method involved taking the pooled fractions from ion exchange and adjusting the protein concentration to 0.1 mg/mL. This material was then exhaustively dialyzed against 20 mM Tris, 0.5 M NaCl, pH 7.4 at 4°C (approximately 1/10,000 dilution over 36 hrs). The other method (infinite dilution) involved taking the pooled fractions from the ion exchange column and dripping the protein containing solution into a buffer containing 20 mM Tris, 500 mM NaCl, 35% glycerol, pH 7.4 at 4°C. The drip rate was approximately 1 mL per 7 minutes and the final protein concentration in the refolding buffer was 0.1 mg/mL. The second methodology for refolding yields slightly more correctly folded protein. The refolded protein is then concentrated using a Millipore ProFlux M12 Tangential Flow Filtration System with a S3Y10 spiral cartridge. Once the material has been concentrated down to 300 mL to 400 mL, it is placed in a 2.5 L Amicon stir cell using YM10 membrane and concentrated to between 40 mL and 80 mL.

The final step in the purification of NGEAs involves preparative size exclusion chromatography. The concentrated refolded protein (40 mL to 80 mL) was placed on a preparative Pharmacia Superdex 75 (60/600) column equilibrated with 20 mM Tris, 1 mM EDTA, 0.5 M NaCl, pH 7.4. The flow rate was 10 mL/min. The protein elution was monitored by UV absorbance at 280 nm. Fractions containing the purified protein were identified by SDS-PAGE, pooled, and stored at -80°C.

- 54 -

Example 3 Purification and  
Characterization of PEGylated EPO analogs

*Preparative Size Exclusion Chromatography (SEC):*

5       The purification of the various PEGylated species of  
non-glycosylated EPO and non-glycosylated EPO analogs was  
achieved by size exclusion chromatography on a Waters 650E  
Advanced Protein Purification System. The protocol utilized  
10   a Superdex 200 (16/60) column equilibrated in 20mM TRIS,  
0.5M NaCl, 1mM EDTA at pH 7.4. Typical, volume loads were  
less than or equal to 2.5 mL. The flow rate was 1 mL/min  
and 1 mL fractions were collected. The column was run at  
room temperature. The protein elution was monitored by UV  
detector at 280nm (Figures 3A and 4A).

15

*Analytical Size Exclusion High Performance Liquid*  
*Chromatography (SEC-HPLC):*

      The PEGylation of non-glycosylated EPO analogs was  
monitored by SEC-HPLC, since the PEG modification makes a  
20   significant impact on the hydrodynamic radius of the  
protein. All analytical assays were performed on a HP1100  
HPLC (Hewlett-Packard). The modification was monitored by  
either of two SEC-HPLC protocols.

      The first protocol utilized a Superdex 200 (PC3.2/300)  
25   column equilibrated in 20 mM TRIS, 0.5 M NaCl, 1 mM EDTA at  
pH 7.4. The flow rate was 50 uL/min and 20 µg of protein  
was typically injected. The column was run at room  
temperature; however, the samples were maintained at 4°C in  
the auto-injector. The protein elution was monitored by UV  
30   detector at 214nm.

      A second protocol utilized a TosohHaas G3000SWXL (7.8 mm  
x 30 cm) column equilibrated in 20mM TRIS, 0.5M NaCl, 1mM  
EDTA at pH 7.4 (Figure 3B and 4B). The flow rate was 0.5  
mL/min and 20 µg of protein was typically injected. The

- 55 -

column was run at room temperature; however, the samples were maintained at 4°C in the auto-injector. The protein elution was monitored by UV detector at 214nm.

5        *Sodium Dodecylsulfate-Polyacrylamide Gel Electrophoresis (SDS-PAGE):*

SDS-PAGE was used to analyze preparative SEC fractions to facilitate pooling of species with similar degrees of PEGylation, as well as to characterize the final pooled  
10 products (Figure 5). All SDS-PAGE analyses were performed on an Novex Powerease 500 system using Novex 16% Tris-Glycine. Pre-cast Gels were run using Novex Tris-Glycine SDS Running Buffer. The staining solution consisted of  
15 0.05% Commassie Brilliant Blue (R250), 30% methanol, and 10% acetic acid. The de-staining solution was 30% methanol and 10% acetic acid. Novex Mark 12 Wide Range Protein Standards were routinely used as for molecular weight standards. Gels were run at 125 V until sample entered gel and then voltage was adjusted to 200V.

20

*Matrix-Assisted Laser Desorption/Ionization-Time of Flight Mass Spectrometry (MALDI-TOF MS):* All experiments were performed on a Micromass TofSpec-2E mass spectrometer fitted with Time Lag Focusing electronics, a Reflectron and  
25 Post Acceleration Detector (or P.A.D., used for high mass detection) The effective path length of the instrument in Linear mode is 1.2 meters, in Reflectron mode it is 2.3 meters.

Two dual micro-channel plate detectors are fitted for  
30 linear and reflectron mode detection. The laser used is a Laser Science Inc. VSL-337i nitrogen laser operating at 337 nm at 10 laser shots per second. All data were acquired using a 500 Mhz, 8 bit transient recorder and up to 100 laser shots were averaged per spectrum using the Post

- 56 -

Acceleration Detector (when necessary to increase ion signal).

The detection efficiency of a micro-channel plate or electron multiplier reduces as the ion mass increases. The operation of these devices relies on the production of secondary electrons from the ion bombardment of a surface and this becomes less efficient as the ion impact velocity reduces. Higher mass ions have lower velocities than low mass ions with the same energy and hence produce less, or no, secondary ions. In order to enhance the detection of high mass ions previous studies have shown that the secondary ion species may be accelerated from a dynode surface place in the ion path into a conventional electron multiplier. The TofSpec-2E has been modified such that an ion-to-ion conversion dynode may be moved in and out of position in front of the standard micro-channel plate detector.

The net effect of the introduction of this ion-to-ion conversion dynode is a small increase in the single mass peak width and so the ability to move the dynode out of the ion path ensures that the resolution at low mass, where the detection efficiency is already high, need not be compromised.

Sinapinic acid was used as the ionization matrix as all masses observed were above 10 kDa. Mass appropriate reference proteins were used for internal and external calibration files in order to obtain accurate mass determinations for the samples analyzed. Samples were all analyzed using a 1:2 sample to matrix dilution. Since the PEGylated samples were extremely heterogeneous they were always prepared in an attempt to obtain the highest concentration possible when spotted onto the plate.

- 57 -

The instrument was initially set up under the following linear high mass detector conditions for PEGylated samples:

5    **Source Voltage:** 20.0 keV            **Pulse Voltage:** 3.6 keV  
     **Extraction Voltage:** 19.9 keV    **Laser Course:** 100  
     **Focus Voltage:** 14.5 keV        **Laser Fine:** 60  
     **Linear detector:** 3.5 keV       **High mass detector:** 12.0 keV  
     **P.A.D.:** (in line)

10

     These settings were then modified (if needed) to give the best signal/noise ratio and highest resolution. Examples of MALDI-Tof MS analysis are shown in Figures 6 and 7.

15

     Table II provides a characterization of different non-glycosylated EPO derivatives of MR-NGE[W5K]-166Δ and MR-NGE-166Δ modified with either PEG (5 kDa)-aldehyde or PEG (20 kDa)-aldehyde (Examples 1a, 1b, and 1g). Species in bold capitalized print were qualitatively identified as the major species using SDS-PAGE and MALDI-Tof analysis. Peak assignments by analytical HPLC-SEC were assigned based upon sequential correlation between degree of PEGylation and retention time. The assignments were also correlated to the species observed by SDS-PAGE and MALDI-Tof analyses. The average degree of PEGylation is the percent-weighted average based upon the analytical HPLC-SEC. For species that were greater than or equal to a certain degree of modification the lowest integer value was used in the calculation.

20  
25

Table II

Cmpd	Protein	PEG Size (kDa) <sup>a</sup>	SDS-PAGE Species	MALDI-Tof Species	Analytical HPLC-SEC Species	Average Degree of PEGylation
AH	MR-NGE- 166Δ	20-SPA	Di-, Tri-, Tetra-	Di-, Tri-, Tetra-	100% Tri	3.0
AM	MR-NGE [W5K]- 166Δ	20	Di-, Tri-, Tetra-, >Tetra	Di-, Tri-, Tetra-	44.2% > Tetra- 43.1% Tri- 12.6% Di-	3.3
B	MR-NGE [W5K]- 166Δ	5	tri-, tetra-, penta-	mono-, di-, tri-, tetra-, , hexa-, septa-, octa-	37.7% tetra- 30.7% tri- 11.6% >penta- 11.0% di-	3.2
C	MR-NGE [W5K]- 166Δ	5	mono-, di-, tri-	mono-, di-, tri-, penta-, , hexa-, speta-, octa-	55.1% di- 18.9% tri- 15.5% tetra- 10.5% mono-	2.4
D	MR-NGE [W5K]- 166Δ	5	mono-, di-, native	native, mono-, di-, penta-, hexa-, septa-	60.5% mono- 19.6% di- 16.0% tri- 3.8% unreacted	1.5
F	MR-NGE [W5K]- 166Δ	20	mono-, di-, ≥tri-	mono-, di-, tri-	64.6% ≥Tri- 27.4% di- 5.0% mono-	2.5



- 59 -

G	MR-NGE [W5K]- 166Δ	20	mono-, di-, ≥tri-	mono-, di-, tri-	37.9% di- 33.3% ≥tri- 28.8% mono-	2.1
Z	MR-NGE- 166Δ	20	mono-	mono-, native	85.2% mono- 7.3% di- 1.4% ≥tri	1.0

\*All compounds with the exception of AH, were PEGylated using a propionaldehyde derivatized methoxy-PEG reagent. Compound AH was PEGylated using the succinimidyl derivative of methoxy-PEG propionic acid (see Example 1q).

*Enzymatic digest of PEGylated species:*

Endoproteinase Lys\_C is a serine proteinase which specifically cleaves on the C-terminal side of lysine residues. A protein sample was typically digested at 200 μg/mL in a solution of 1M guanidine hydrochloride, 20mM Tris, 1mM EDTA, pH 8 containing 10 μg/mL Lys\_C (Promega) for 3 hours at 37°C. The digested protein was reduced by addition of 10mM DTT for 10 minutes at 37°C, then quenched by addition of 10% (v/v) of a 1% TFA solution. The resulting peptide fragments were separated by reversed-phase HPLC on a Zorbax-SB C8 column using a TFA/ACN mobile phase (A-buffer: 0.1% TFA, B-buffer: 0.1% TFA in 80% ACN) at 1 mL/min. The peptide mixture was injected onto the column equilibrated at 10% B, after five minutes the gradient was increase at 1%B per minute for 55 minutes. HPLC peaks were identified by MALDI-Tof, LC-MS, and/or N-terminal analysis.

As illustrated in Figure 8, peptide mapping has been used to characterize N-terminally modified proteins. The peptide map of Compound Z reveals that peptide L1 is modified by the PEGylation process and elutes later and with a broader profile indicative of a peptide covalently modified with a heterogeneous, 20K PEG moiety. Note, the

- 60 -

PEG(20kDa)-L1 peptide has been identified as the N-terminal fragment of MR-HIP, i.e., PEG(20K)-Met-Arg-Ala-Pro-Pro-Arg-Leu-Ile-Cys-Asp-Ser-Arg-Val-Leu-Glu-Arg-Tyr-Leu-Leu-Glu-Ala-Lys.

5

*Physical stability studies:*

The physical stability of various proteins were studied using a Dynamic Light Scattering (DLS) assay to monitor protein aggregation as function of size. A protein solution was diluted to either a) 20mM Tris, 500mM NaCl, 1mM EDTA (simulated processing conditions), b) 20mM Tris, 150mM NaCl, 1mM EDTA (simulated physiological conditions), or c) 20mM Tris, 150mM NaCl, 3 mg/mL m-Cresol, 1mM EDTA (simulated formulation conditions), containing 0.1 mg/mL protein. Solution pH was adjusted to 7.4 ( $\pm 0.05$ ) with HCl/NaOH and filtered through a Millex-GV filter (4 mm, 0.2 $\mu$ ) into a 6 x 50mm borasilica type-I glass tube. The average light-scatter intensity weighted particle size was collected on a Brookhaven BI900 Instrument consisting of a goniometer at a 90° angle, digital correlator, and a Lexel model 3500 argon ion laser adjusted to the 488-nm line. The experimentally determined autocorrelation function  $C(t)$  was analyzed by the cumulants method to yield the weight-averaged hydrodynamic diameter. A plot of hydrodynamic diameter versus incubation time at 37°C resulted in an exponential-like curve. The time before a significant change in particle size, or lag time, was determined by fitting linear lines to the pre-growth and growth phase data points. The intersection was defined as the lag time.

30 The physical stability of MR-NGE-166 $\Delta$  and N-terminal 20 kDa mono-PEGylated MR-NGE-166 $\Delta$  was monitored by dynamic light scattering under high ionic strength, physiological ionic strength, and formulation conditions. The pH and temperature of the experiments were 7.4 and 37°C,

- 61 -

respectively. The results are presented in Table III. Aggregation was assessed by changes in size determined by quadratic fits to the auto-correlation function. The data in Table III show that N-terminal PEGylation of MR-NGE-166Δ with 20 kDa moiety dramatically increases the lag time before aggregation begins and slows the growth rate of aggregation after it has initiated.

Table III

Solvent Condition	MR-NGE-166Δ		N-terminal 20 kDa mono-PEGylated MR-NGE-166Δ	
	Lag Time (Hr)	Growth Rate (nm/Hr)	Lag Time (Hr)	Growth Rate (nm/Hr)
500mM NaCl	9.5	124	>74	---
150mM NaCl	0.1	334	83	0.07
150mM NaCl + m-Cresol	*	*	28	41

10 \*Solution immediately precipitated upon cresol addition

Example 4 In Vitro activity of non-glycosylated EPO analogs with and without PEGylation:

In vitro Assay:

15 The bioactivity was determined using the method of Krystal [17]. Briefly, B6CF1 mice were treated with daily injections of phenylhydrazine (60 mg/kg) for two consecutive days. Phenylhydrazine treatment induce a 10x increase in spleen size and renders an organ enriched with EPO responsive cells. On the third day, the spleens are removed and teased into Alpha MEM without ribonucleosides and deoxyribonucleosides. The cell suspension is then filtered through a 200-gauge nylon mesh, cell density determined, and a spleen cell mixture prepared. The spleen cell mixture

20

- 62 -

contained  $4 \times 10^6$  cells/mL spleen cells, 20% fetal calf serum (FCS), and 0.1mM b-mercaptoethanol (BME) in a-MEM without ribonucleosides and deoxyribonucleosides (a-N). The spleen cell mixture was plated into microtiter plates at  
5 volume of 0.05 mL/well. The NEG, NEGA, PEGylated NGE, PEGylated NEGA and EPOGEN<sup>®</sup> test samples were added to each well.

Each test sample was diluted with bioassay medium containing 78% Alpha-MEM, 20% heat-inactivated FCS, 1% BME  
10 and 1% penicillin/streptomycin/fungizone and 0.05 mL was added per well. Sample dilutions ranged from  $10^1$  to  $10^9$ . Cultures were incubated for 22hrs at 37°C in a humidified atmosphere of 5% CO<sub>2</sub>, 95% air. After this initial  
15 incubation, 20uL of <sup>3</sup>H-thymidine stock containing ~50uCi/mL in a-N was added to each well. The culture were then incubated at 37°C for an additional two hours. The cellular contents were then harvested by filtration using a glass  
20 fiber filter impregnated with scintillant. The cellular rentate was washed with distilled water and the filters dried with methanol. The extent of <sup>3</sup>H-thymidine into DNA  
stimulated by NEG, NEGA, PEGylated NGE, PEGylated NEGA and EPOGEN<sup>®</sup> test samples was determined on a Beckman LS3801  
liquid scintillation counter. The standard curve was calibrated against the World Health Organization Second  
25 International Reference Preparation.

PEGylation of MR-NGE[W5K]-166A and MR-NGE-166A yielded a variety of modified species that exhibit both *in vivo* and *in vitro* activity. Non-glycosylated EPO analogs were modified as described in Example 1 and separated into  
30 various species pools based on the degree of PEGylation. Size Exclusion Chromatography as described in Example 3 was used to separate the PEGylated species. The *in vitro* results obtained for the <sup>3</sup>H-thymidine assay described above are presented in Table IV and Figure 9.

Table IV: *In vitro* activity, as monitored by the  $^3\text{H}$ -thymidine uptake assay in spleen cells, of various compounds.

5

Compound	Protein	Approx. # of PEG	PEG Size (kDa)*	log (U/mg)	Std Dev	Std Err Mean
MRNGE166Δ	std	0		5.12	0.13	0.05
MRNGE166Δ	std	0		5.35	0.25	0.08
MRNGE166Δ	std	0		5.34	0.06	0.04
MRNGE166Δ	std	0		5.73	0.17	0.05
MRNGE166Δ	std	0		5.37	0.11	0.03
AA	MRNGE 166Δ	0	20	6.12	0.18	0.04
AB	MRNGE 166Δ	1.0	5	5.50	0.34	0.09
AC	MRNGE [W5E] 166Δ	1.0	5	5.59	0.18	0.05
AD	MRNGE [W5K] 166Δ	1.0	5	5.75	0.28	0.08
AE	MRNGE [W5E] 166Δ	1.0	20	5.38	0.22	0.06
AF	MRNGE [W5K] 166Δ	1.0	20	5.48	0.41	0.15
AH	MRNGE 166Δ	3.0	20-SPA*	2.19	0.17	0.06
AI	MRNGE 166Δ	2.4	20-SPA	3.23	0.13	0.04

- 64 -

AJ	MRNGE 166Δ	1.6	20-SPA	4.56	0.29	0.08
AK	MRNGE [W5K] 166Δ	2.5	20	3.18	0.76	0.18
AL	MRNGE [W5K] 166Δ	2.8	20	3.30	0.35	0.10
AM	MRNGE [W5K] 166Δ	3.3	20	3.31	0.34	0.11
B	MRNGE [W5K] 166Δ	3.2	5	4.26	0.13	0.03
C	MRNGE [W5K] 166Δ	2.4	5	5.09	0.09	0.03
D	MRNGE [W5K] 166Δ	1.5	5	5.16	0.07	0.02
F	MRNGE [W5K] 166Δ	2.5	20	3.59	0.09	0.03
H	MRNGE [W5K] 166Δ	8.0	5	1.26	0.02	0.01
I	MRNGE [W5K] 166Δ	4.5	5	2.80	0.07	0.03
J	MRNGE [W5K] 166Δ	3.0	5	3.86	0.07	0.03

- 65 -

K	MRNGE [W5K] 166Δ	2.0	5	4.65	0.03	0.02
L	MRNGE [W5K] 166Δ	1.0	5	5.18	0.05	0.03
M	MRNGE [W5K] 166Δ	0.0	5	5.06	0.06	0.04
N	MRNGE 166Δ	7.0	5	1.00		
O	MRNGE 166Δ	4.5	5	2.78	0.11	0.03
P	MRNGE 166Δ	2.5	5	3.77	0.11	0.05
Q	MRNGE 166Δ	2.0	5	4.04	0.09	0.05
R	MRNGE 166Δ	1.0	5	5.12	0.13	0.04
S	MRNGE 166Δ	0.0	5	5.23	0.12	0.04
T	MRNGE 166Δ	3.8	5	3.13	0.38	0.17
U	MRNGE 166Δ	3.3	5	3.65	0.28	0.12
V	MRNGE 166Δ	2.3	5	3.89	0.28	0.10
W	MRNGE 166Δ	1.8	5	4.90	0.11	0.03
X	MRNGE 166Δ	1.2	5	5.07	0.22	0.06

- 66 -

Y	MRNGE 166Δ	1.9	20	4.42	0.12	0.03
Z	MRNGE 166Δ	1.0	20	4.90	0.15	0.04

\*All compounds with the exception of AH, AI, and AJ, were PEGylated using a propionaldehyde derivatized methoxy-PEG reagent. Compounds AH, AI, and AJ were PEGylated using  
 5 the succinimidyl derivative of methoxy-PEG propionic acid.

Example 5: In Vivo testing of non-glycosylated EPO  
 analogs with and without PEGylation:

In Vivo Assay:

10 Groups of four to six female B6CF1, C57BL/6J, or CD-1 mice, ranging in age from 5 - 8 weeks, were used to assess *in vivo* activity. Changes in hematocrit levels were used as the indicator of *in vivo* activity. To establish a baseline prior to dosing, the mice were anesthetized and the baseline  
 15 hematocrit established by filling two heparinized micro-hematocrit tubes from the retro-orbital venous plexus. Each animal was weighted and marked for identification through the study. The mice received either a single subcutaneous injection per week of PEGylated NGE, PEGylated NEGA, or  
 20 EPOGEN®. PEGylated NGE, PEGylated NEGA, and EPOGEN® were dosed at either 10, 20, 50, or 100 ug/kg. Hematocrit levels were determined on days 0, 7, 10, and 14. Control animals were injected with PBS containing 2.5% BSA.

PEGylation of MR-NGE[W5K]-166Δ and MR-NGE-166Δ yielded  
 25 a variety of modified species that exhibited both *in vivo* and *in vitro* activity. Non-glycosylated EPO analogs were modified as described in Example 1 and separated into various species pools based on the degree of PEGylation. Size Exclusion Chromatography as described in Example 3 was  
 30 used to separate the PEGylated species. The *in vivo* results



- 67 -

were monitored by hematocrit levels as described above and are presented in Tables V, VI, and VII.

5 Table V: Change in hematocrit after a single, s.c.- administered dose of compound on day 0. Hematocrit measurements were performed on days 0 and 7. The difference between day 7 and day 0 is reported as Delta within this table.

Compound	PEG Size (kDa)	Number of PEG Moieties	Delta (day 7-day0) per Dose (ug/kg)				
			0	10	20	50	100
PBS/BSA			-1.4 ( $\pm$ 2.2)				
EPO				-0.5 ( $\pm$ 1.9)	1.6 ( $\pm$ 3.9)	2.4 ( $\pm$ 3.0)	4.9 ( $\pm$ 1.1)
C	5	2.4		-0.6 ( $\pm$ 1.6)			1.4 ( $\pm$ 2.0)
F	20	2.5			0.9 ( $\pm$ 0.8)	7.9 ( $\pm$ 2.4)	11.0
G	20	2.1		-0.2 ( $\pm$ 1.6)	0.6 ( $\pm$ 1.7)	5.4 ( $\pm$ 1.8)	7.2 ( $\pm$ 2.1)
Z	20	1.0			0.1 ( $\pm$ 1.9)	-0.5 ( $\pm$ 1.5)	3.6 ( $\pm$ 1.4)
AH	20	3.0			-2.2 ( $\pm$ 1.2)		
AM	20	3.3			1.2 ( $\pm$ 3.3)	4.8 ( $\pm$ 2.2)	

10 Table VI: Change in hematocrit after a single, subcutaneous administered dose of the compound at Day 0. Hematocrit measurements were performed on days 0, 7, and 10. The difference between day 10 and day 0 is reported as Delta within this table.

Compound	PEG Size (kDa)	Number of PEG Moieties	Delta (day 10-day0) per Dose (ug/kg)			
			0	10	20	50
PBS/BSA			-3.5 ( $\pm$ 2.5)			
EPO				-0.9 ( $\pm$ 1.0)	-5.2 ( $\pm$ 3.5)	-1.2 ( $\pm$ 2.9)
AH	20	3.0			-3.0 ( $\pm$ 1.3)	
AM	20	3.3			2.1 ( $\pm$ 3.1)	2.0 ( $\pm$ 3.5)

15

- 68 -

Table VII: Change in hematocrit after a single, s.c.-administered dose of the compound at Day 0. Hematocrit measurements were performed on days 0, 7, 10, and 14. The difference between day 14 and day 0 is reported as Delta within this table.

Compound	PEG Size (kDa)	Est. # of PEG Moieties	Delta (day 14-day0) per Dose (ug/kg)		
			0	20	50
PBS/BSA			-3.1 ( $\pm 4.3$ )		
EPO					-0.7 ( $\pm 1.2$ )
AM	20	3.3		2.1 ( $\pm 0.9$ )	-2.3 ( $\pm 1.9$ )

*Pharmacokinetic Assay:* Compounds C and G were administered by either intravenous or subcutaneous injection. Fischer 334 male rats were dosed at 10  $\mu\text{g/kg}$  levels. Three animals were used per time point per compound. Blood samples were collected at 15 min, 30 min, 1, 3, 5, 8, 24, and 48 hours after dosing for intravenous dosing. Blood samples were collected at 0, 2, 5, 8, 24, 48, 72, 96, and 120 hours after subcutaneous dosing.

A sandwich ELISA assay was used to measure concentrations of erythropoietin-like immunoreactivity in the plasma. The assays were validated to the following levels:

Compound C: Upper limit of quantitation 600 pg/mL.  
Lower limit of quantitation 25 pg/mL  
Compound G: Upper limit of quantitation 1200 pg/mL.  
Lower limit of quantitation 100 pg/mL

The pharmacokinetic results are presented in Table VIII and Figure 14. A similar protocol was used to collect the data present in Figure 2.

- 69 -

Table VIII: Pharmacokinetic Parameters of Erythropoietin-like Immunoreactivity in Male Fischer 344 Rats After IV or SQ Administration of Compounds C and G (Table II).

Statistics\Subject	Compound C		Compound G	
	IV	SQ	IV	SQ
AUC (pg*hr/mL)&	38247	17943	751771	186546
AUC (pg*hr/mL)%	-	18182	-	239999
HalfLife (h)	10	11	NC*	NC*
C <sub>max</sub> (pg/mL)	86931	576	126132	3904
T <sub>max</sub> (h)	0.25	5	0.25	48
Absolute Bioavailability^	-	47	-	25
Relative Bioavailability#	-	4.4	-	46

5 ^ AUC from 0-48 h

^AUC from 0-120h

\*No calculation, insufficient terminal data points

^AUC SC<sub>(0-48h)</sub>/AUC IV<sub>(0-48h)</sub>

\*(AUC G SC<sub>0-48h</sub>) / (AUC EPOGEN SC<sub>0-48h</sub>)

- 70 -

WE CLAIM:

1. A protein selected from the group consisting of:
  - a) NGE;
  - 5 b) NGE[5E];
  - c) MR-NGE;
  - d) MR-NGE-88E;
  - e) MR-NGE-88K;
  - f) MR-NGE-88P;
  - 10 g) MR-NGE-88S;
  - h) MR-NGE[4E];
  - i) MR-NGE[5E];
  - j) MR-NGE[5K];
  - k) MR-NGE[W5E]; and
  - 15 l) MR-NGE[W5K].
  
2. A protein selected from the group consisting of:
  - a) NGE-166 $\Delta$ ;
  - b) NGE[5E]-166 $\Delta$ ;
  - 20 c) MR-NGE-166 $\Delta$ ;
  - d) MR-NGE-88E-166 $\Delta$ ;
  - e) MR-NGE-88K-166 $\Delta$ ;
  - f) MR-NGE-88P-166 $\Delta$ ;
  - g) MR-NGE-88S-166 $\Delta$ ;
  - 25 h) MR-NGE[4E]-166 $\Delta$ ;
  - i) MR-NGE[5E]-166 $\Delta$ ;
  - j) MR-NGE[5K]-166 $\Delta$ ;
  - k) MR-NGE[W5E]-166 $\Delta$ ; and
  - 30 l) MR-NGE[W5K]-166 $\Delta$ .
  
3. The protein of Claim 2, wherein the protein is MR-NGE-166 $\Delta$ .

- 71 -

4. The protein of Claim 2, wherein the protein is MR-NGE[W5K]-166Δ.

5. The protein of Claim 2, wherein the protein is MR-NGE[W5E]-166Δ.

6. An erythropoietic compound having a protein portion and a polymer portion, wherein the protein portion is selected from the group consisting of: non-glycosylated human erythropoietin and non-glycosylated erythropoietin analogs and wherein the polymer portion consists of 1 to 5 polymer chains of the formula:

$$[R-O-(CH_2CH_2-O)_X-(CH_2)_Y-NH]$$

wherein R is H or C<sub>1</sub> to C<sub>4</sub> alkyl, X is a number from about 70 to about 1200, and Y is a number from 1 to 4; and the polymer chain is covalently bonded to the protein portion by a secondary amine bond.

7. The erythropoietic compound of Claim 6 wherein X is a number from about 225 to about 1200.

8. The erythropoietic compound of Claim 7 wherein X is a number from about 340 to about 1200.

9. The erythropoietic compound of Claim 8 wherein X is a number from about 450 to about 1200.

10. The erythropoietic compound of Claim 9 wherein X is a number from about 450 to about 700.

- 72 -

11. The erythropoietic compound of any one of Claims 6 through 10 wherein the protein portion is a non-glycosylated erythropoietin analog and the polymer portion is bound to  
5 the protein portion at the N-terminus of the protein.

12. The erythropoietic compound of any one of Claims 6 through 10 wherein the protein portion is a protein of  
10 Claim 1.

13. The erythropoietic compound of any one of Claims 6 through 10 wherein the protein portion is a protein of  
Claim 2.

14. A protein which is the product of the expression in a host cell of an exogenous DNA sequence comprising a DNA sequence encoding at least one of the proteins of  
15 Claim 1 or 2.

15. The erythropoietic compound of any one of Claims 6 through 10 made by a process comprising the steps of:

- 20 a) adding a polyethylene glycol-aldehyde polymer to a solution of non-glycosylated erythropoietic protein under conditions that permit the  
25 formation of an imine bond between an amino group of the protein and the aldehyde group of the polymer; and  
b) adding a reducing agent to reduce the imine bond to a secondary amine bond.

16. An isolated nucleic acid sequence, comprising a polynucleotide encoding a protein of Claim 1 or  
30 Claim 2.

- 73 -

17. An isolated nucleic acid sequence, comprising a polynucleotide which is SEQ ID NO:2.

5        18. A vector comprising a nucleic acid sequence according to Claim 16 or 17.

19. A host cell comprising the vector of Claim 18.

10       20. A host cell expressing at least one protein of Claim 1 or Claim 2.

21. The host cell of Claim 19 or 20 wherein said host cell is *E. coli*.

15

22. A transgenic or chimeric non-human animal, comprising at least one host cell according to Claim 20.

20       23. A process for producing a protein comprising the steps of transcribing and translating the isolated nucleic acids of Claims 16 or 17 under conditions that the protein is expressed in detectable amounts.

25       24. A process for preparing polymer-derivatized, non-glycosylated erythropoietic compounds, comprising the steps of:

- 30           a) adding a polyethylene glycol-aldehyde polymer to a solution of non-glycosylated erythropoietic protein under conditions that permit the formation of an imine bond between an amino group of the protein and the aldehyde group of the polymer; and
- b) adding a reducing agent to reduce the imine bond to a secondary amine bond.

35

- 74 -

25. The process of Claim 24, wherein the aldehyde polymer and the protein in the solution are present at a ratio of 0.08 to 24 on a mole polymer per mole protein basis.

26. The process of Claim 25, wherein the ratio of aldehyde polymer to protein is 1 to 10.

27. The process of any one of Claims 24 through 26, wherein the solution is buffered and the added reducing agent is selected from the group consisting of sodium cyanoborohydride and sodium borohydride.

28. The process of Claim 27, wherein the solution is borate-phosphate buffered with a pH between 7 and 9 and said reducing agent is sodium cyanoborohydride.


29. A method for increasing the hematocrit levels in a mammal comprising the administration of a therapeutically effective amount of an erythropoietic compound of any one of Claims 6 through 10.


30. The use of an erythropoietic compound as claimed in any one of Claims 6 through 10 for the manufacture of a medicament for the treatment of patients with insufficient hematocrit levels.



31. A pharmaceutical formulation adapted for the treatment of patients with insufficient hematocrit levels comprising an erythropoietic compound of Claims 6 through 10.



32. An erythropoietic compound as hereinbefore described with reference to any one of the Examples.





**Fig. 1**


**Fig. 2**


**Fig. 3**

**Fig. 4**


**Fig. 5**


**Fig. 6**


**Fig. 7**


**Fig. 8**




**Fig. 9**

**Fig. 10**


**Fig. 11**

**Fig. 12**

**Fig. 13**

**Fig. 14**

to Male Fischer 344 Rats



## SEQUENCE LISTING

&lt;110&gt; Eli Lilly and Company

&lt;120&gt; ERYTHROPOIETIC COMPOUNDS

&lt;130&gt; X-12553

&lt;140&gt;

&lt;141&gt;

&lt;160&gt; 3

&lt;170&gt; PatentIn Ver. 2.0

&lt;210&gt; 1

&lt;211&gt; 193

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 1

Met Gly Val His Glu Cys Pro Ala Trp Leu Trp Leu Leu Ser Leu  
 1 5 10 15

Leu Ser Leu Pro Leu Gly Leu Pro Val Leu Gly Ala Pro Pro Arg Leu  
 20 25 30

Ile Cys Asp Ser Arg Val Leu Glu Arg Tyr Leu Leu Glu Ala Lys Glu  
 35 40 45

Ala Glu Asn Ile Thr Thr Gly Cys Ala Glu His Cys Ser Leu Asn Glu  
 50 55 60

Asn Ile Thr Val Pro Asp Thr Lys Val Asn Phe Tyr Ala Trp Lys Arg  
 65 70 75 80

Met Glu Val Gly Gln Gln Ala Val Glu Val Trp Gln Gly Leu Ala Leu  
 85 90 95

Leu Ser Glu Ala Val Leu Arg Gly Gln Ala Leu Leu Val Asn Ser Ser  
 100 105 110

Gln Pro Trp Glu Pro Leu Gln Leu His Val Asp Lys Ala Val Ser Gly  
 115 120 125

Leu Arg Ser Leu Thr Thr Leu Leu Arg Ala Leu Gly Ala Gln Lys Glu  
 130 135 140

Ala Ile Ser Pro Pro Asp Ala Ala Ser Ala Ala Pro Leu Arg Thr Ile  
 145 150 155 160

Thr Ala Asp Thr Phe Arg Lys Leu Phe Arg Val Tyr Ser Asn Phe Leu  
 165 170 175

Arg Gly Lys Leu Lys Leu Tyr Thr Gly Glu Ala Cys Arg Thr Gly Asp  
 180 185 190

Arg

<210> 2

<211> 498

<212> DNA

<213> synthetic construct

<220>

<221> CDS

<222> (1)..(504)

<220>

<221> CDS

<222> (1)..(498)

<220>

<221> CDS

<222> (1)..(498)

<400> 2

gct cca cca cgt ctt att tgt gat tct cgt gtt ctt gaa cgt tac ctg 48  
 Ala Pro Pro Arg Leu Ile Cys Asp Ser Arg Val Leu Glu Arg Tyr Leu  
 1 5 10 15

ctg gaa gct aaa gaa gct gaa aac atc acc acc ggt tgc gct gaa cac 96  
 Leu Glu Ala Lys Glu Ala Glu Asn Ile Thr Thr Gly Cys Ala Glu His  
 20 25 30

tgc tcc ctg aac gaa aac atc acc gtt ccg gac acc aaa gtt aac ttc 144  
 Cys Ser Leu Asn Glu Asn Ile Thr Val Pro Asp Thr Lys Val Asn Phe  
 35 40 45

tac gct tgg aaa cgt atg gaa gtt ggt cag cag gct gtt gaa gtt tgg 192  
 Tyr Ala Trp Lys Arg Met Glu Val Gly Gln Gln Ala Val Glu Val Trp  
 50 55 60

cag ggt ctg gct ctg ctg tcc gaa gct gtt ctg cgt ggt cag gct ctg 240



Gln Gly Leu Ala Leu Leu Ser Glu Ala Val Leu Arg Gly Gln Ala Leu  
 65 70 75 80  
 ctg gtt aac tcc tcc cag ccg tgg gaa ccg ctg cag ctg cac gtt gac 288  
 Leu Val Asn Ser Ser Gln Pro Trp Glu Pro Leu Gln Leu His Val Asp  
 85 90 95  
 aaa gct gtt tcc ggt ctg cgt tcc ctg acc acc ctg ctg cgt gct ctg 336  
 Lys Ala Val Ser Gly Leu Arg Ser Leu Thr Thr Leu Leu Arg Ala Leu  
 100 105 110  
 ggt gct cag aaa gaa gct atc tcc ccg ccg gac gct gct tcc gct gct 384  
 Gly Ala Gln Lys Glu Ala Ile Ser Pro Pro Asp Ala Ala Ser Ala Ala  
 115 120 125  
 ccg ctg cgt acc atc acc gct gac acc ttc cgt aaa ctg ttc cgt gtt 432  
 Pro Leu Arg Thr Ile Thr Ala Asp Thr Phe Arg Lys Leu Phe Arg Val  
 130 135 140  
 tac tcc aac ttc ctg cgt ggt aaa ctg aaa ctg tac acc ggt gaa gct 480  
 Tyr Ser Asn Phe Leu Arg Gly Lys Leu Lys Leu Tyr Thr Gly Glu Ala  
 145 150 155 160  
 tgc cgt acc ggt gac tga 498  
 Cys Arg Thr Gly Asp  
 165

&lt;210&gt; 3

&lt;211&gt; 165

&lt;212&gt; PRT

&lt;213&gt; synthetic construct

&lt;400&gt; 3

Ala Pro Pro Arg Leu Ile Cys Asp Ser Arg Val Leu Glu Arg Tyr Leu  
 1 5 10 15  
 Leu Glu Ala Lys Glu Ala Glu Asn Ile Thr Thr Gly Cys Ala Glu His  
 20 25 30  
 Cys Ser Leu Asn Glu Asn Ile Thr Val Pro Asp Thr Lys Val Asn Phe  
 35 40 45  
 Tyr Ala Trp Lys Arg Met Glu Val Gly Gln Gln Ala Val Glu Val Trp  
 50 55 60  
 Gln Gly Leu Ala Leu Leu Ser Glu Ala Val Leu Arg Gly Gln Ala Leu  
 65 70 75 80

Leu Val Asn Ser Ser Gln Pro Trp Glu Pro Leu Gln Leu His Val Asp  
85 90 95

Lys Ala Val Ser Gly Leu Arg Ser Leu Thr Thr Leu Leu Arg Ala Leu  
100 105 110

Gly Ala Gln Lys Glu Ala Ile Ser Pro Pro Asp Ala Ala Ser Ala Ala  
115 120 125

Pro Leu Arg Thr Ile Thr Ala Asp Thr Phe Arg Lys Leu Phe Arg Val  
130 135 140

Tyr Ser Asn Phe Leu Arg Gly Lys Leu Lys Leu Tyr Thr Gly Glu Ala  
145 150 155 160

Cys Arg Thr Gly Asp  
165

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
8 June 2000 (08.06.2000)

PCT

(10) International Publication Number  
WO 00/32772 A3

- (51) International Patent Classification<sup>7</sup>: C12N 15/12, 1/21, C07K 14/505, A61K 47/48, 38/18, A01K 67/027, A61P 7/06
- (21) International Application Number: PCT/US99/27801
- (22) International Filing Date:  
23 November 1999 (23.11.1999)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:  
60/110,289 30 November 1998 (30.11.1998) US
- (71) Applicant (for all designated States except US): ELI LILLY AND COMPANY [US/US]; Lilly Corporate Center, Indianapolis, IN 46285 (US).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): BEALS, John, Michael [US/US]; 6710 Bluffridge Parkway, Indianapolis, IN 46278-1853 (US). GLAESNER, Wolfgang [DE/US]; 7512 Fieldstone Court, Indianapolis, IN 46254 (US). MICANOVIC, Radmilla [US/US]; 7126 White Oak Trail, Indianapolis, IN 46236 (US). MILLICAN, Rohn, Lee, Jr. [US/US]; 5319 Deer Creek Avenue, Indianapolis, IN 46254 (US). WITCHER, Derrick, Ryan [US/US]; 10898 Parrot Court, Fishers, IN 46038 (US).
- (74) Agents: STEWART, Mark, J. et al.; Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285 (US).
- (81) Designated States (national): AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.
- (84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).
- Published:  
— With international search report.
- (88) Date of publication of the international search report:  
31 May 2001
- (15) Information about Correction:  
Previous Correction:  
see PCT Gazette No. 48/2000 of 30 November 2000, Section II
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

WO 00/32772 A3

(54) Title: ERYTHROPOIETIC COMPOUNDS

(57) Abstract: The present invention addresses the need for better pharmaceutical agents for treating anemias by providing polymer derivatized non-glycosylated erythropoietic compounds which show stability and bioactivity *in vivo*. The invention further provides methods for preparing these derivatized proteins which involves the use of a linkerless aldehyde modification process.

## INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 99/27801

## A. CLASSIFICATION F SUBJECT MATTER

IPC 7 C12N15/12 C12N1/21 C07K14/505 A61K47/48 A61K38/18  
 A01K67/027 A61P7/06

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C12N C07K A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WASLEY L.C. ET AL.: "The importance of N- and O-linked oligosaccharides for the biosynthesis and in vitro and in vivo biologic activities of erythropoietin" BLOOD, vol. 77, no. 12, 15 June 1991 (1991-06-15), pages 2624-2632, XP000907435 the whole document	1-3, 14, 16-23, 32
X	WO 91 05867 A (AMGEN INC) 2 May 1991 (1991-05-02) figure 8	1-3, 14, 16-23, 32
	---	
	---	
	-/--	

☒ Further documents are listed in the continuation of box C.☒ Patent family members are listed in annex.

## \* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"Z" document member of the same patent family

Date of the actual completion of the international search

26 May 2000

Date of mailing of the international search report

05.09.00

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
 NL - 2280 HV Rijswijk  
 Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
 Fax: (+31-70) 340-3016

Authorized officer

Galli, I

# INTERNATIONAL SEARCH REPORT

International Application No

PC US 99/27801

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	FRANCIS G.E. ET AL.: "PEGylation of cytokines and other therapeutic proteins and peptides: the importance of biological optimisation of coupling techniques" INT. J. HEMATOL., vol. 68, no. 1, July 1998 (1998-07), pages 1-18, XP000907109 cited in the application the whole document figure 7	6-11,15, 24-31
A	--- WO 98 32466 A (FRANCIS GILLIAN ELIZABETH ; FISHER DEREK (GB); MALIK FAROOQ (GB); P) 30 July 1998 (1998-07-30) abstract page 1 -page 5 example 8	1-3,6-32
A	--- DUBE S ET AL: "GLYCOSYLATION AT SPECIFIC SITES OF ERYTHROPOIETIN IS ESSENTIAL FOR BIOSYNTHESIS, SECRETION, AND BIOLOGICAL FUNCTION" JOURNAL OF BIOLOGICAL CHEMISTRY,US,AMERICAN SOCIETY OF BIOLOGICAL CHEMISTS, BALTIMORE, MD, vol. 263, no. 33, 25 November 1988 (1988-11-25), pages 17516-17521, XP002053702 ISSN: 0021-9258 the whole document	1-3,6-32
A	--- WO 96 11953 A (AMGEN INC) 25 April 1996 (1996-04-25) example 2 claims 1,3-6,12,15-17	24-28
A	--- WO 94 25055 A (ABBOTT LAB ; OKASINSKI GREGORY F (US); DEVRIES PETER J (US); MELLOV) 10 November 1994 (1994-11-10) abstract -----	1-3,6-32

# INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US 99/27801

## Box I Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:  
  
Although claim 29 is directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. ☒ Claims Nos.:  
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:  
  
see FURTHER INFORMATION sheet PCT/ISA/210
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of Item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☒ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:  
  
Claims 3, 17 completely, Claims 1, 2, 6-16, 18-32 partially.

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.2

Claims 1-3,14,16-23,32 relate in part to a generic "NGE", without clearly specifying what this actually means. For the purpose of the search, it has been assumed, in the light of Table I and of the definition given on page 12, lines 7-17, that NGE represents a non-glycosylated form of the wild type erythropoietin sequence (e.g., expressed in non-glycosylating cells).

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

1. Claims: (3,17) - completely; (1,2,6-16,18-32) - partly

A non-glycosylated erythropoietin (NGE) polypeptide selected from:

NGE,  
NGE-166del,  
MR-NGE,  
MR-NGE-166del.

Corresponding nucleic acids, vectors, host cells, transgenic animals, production methods.

Corresponding erythropoietic compound comprising said NGE and a polymer portion, wherein the polymer portion consists of 1 to 5 chains of formula  $[R-O-(CH_2CH_2-O)_x-(CH_2)_y-NH]$ , wherein R is H or C1 to C4 alkyl, x is a number from about 70 to 1200, and y is a number from 1 to 4, and the polymer chain is covalently bonded to the protein portion by a secondary amine; and a process for preparing said compound.

2. Claims: (1,2,6-16,18-32) - partly

Idem as subject-matter 1, but wherein the erythropoietin is a non-glycosylated erythropoietin (NGE) analog polypeptide selected from:

NGE-5E,  
NGE-5E-166del,  
MR-NGE-5E,  
MR-NGE-5E-166del  
MR-NGE-88E/K/P/S,  
MR-NGE-88E/K/P/S-166del  
MR-NGE-4E,  
MR-NGE-4E-166del

3. Claims: (4,5) - completely; (1,2,6-16,18-32) - partly

Idem as subject-matter 1, but wherein the erythropoietin is a non-glycosylated erythropoietin (NGE) analog polypeptide selected from:

NGE-W5E,  
NGE-W5E-166del,  
MR-NGE-W5K  
MR-NGE-W5K-166del

4. Claims: (6-11,15,24-32) - partly



FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

As far as not covered by inventions 1-3:

An erythropoietic compound comprising a non-glycosylated human erythropoietin (or a non-glycosylated erythropoietin analog) and a polymer portion, wherein the polymer portion consists of 1 to 5 chains of formula  $[R-O-(CH_2CH_2-O)_x-(CH_2)_y-NH]$ , wherein R is H or C1 to C4 alkyl, x is a number from about 70 to 1200, and y is a number from 1 to 4, and the polymer chain is covalently bonded to the protein portion by a secondary amine; and a process for preparing said compound.

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PC /US 99/27801

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9105867 A	02-05-1991	AT 146187 T	15-12-1996
		AT 184914 T	15-10-1999
		AU 646822 B	10-03-1994
		AU 6604290 A	16-05-1991
		CA 2027635 A	14-04-1991
		CA 2165694 A	14-04-1991
		CN 1051936 A	05-06-1991
		DE 69029370 D	23-01-1997
		DE 69029370 T	05-06-1997
		DE 69033301 D	28-10-1999
		DE 69033301 T	20-04-2000
		DK 428267 T	09-06-1997
		EP 0428267 A	22-05-1991
		EP 0668351 A	23-08-1995
		ES 2097753 T	16-04-1997
		ES 2139764 T	16-02-2000
		FI 964648 A	21-11-1996
		GR 3022658 T	31-05-1997
		HK 1006718 A	12-03-1999
		JP 8151398 A	11-06-1996
		JP 2983629 B	29-11-1999
		JP 4502331 T	23-04-1992
		NO 301832 B	15-12-1997
		NZ 235676 A	28-04-1992
		PT 95586 A,B	30-09-1991
		US 5856298 A	05-01-1999
		ZA 9008166 A	28-08-1991
WO 9832466 A	30-07-1998	AU 5773798 A	18-08-1998
		EP 0921817 A	16-06-1999
WO 9611953 A	25-04-1996	US 5824784 A	20-10-1998
		AT 179991 T	15-05-1999
		AU 706700 B	24-06-1999
		AU 1841995 A	06-05-1996
		AU 4887099 A	11-11-1999
		CA 2178752 A	25-04-1996
		CN 1139932 A	08-01-1997
		DE 69509628 D	17-06-1999
		DE 69509628 T	16-09-1999
		EP 0733067 A	25-09-1996
		EP 0822199 A	04-02-1998
		ES 2131811 T	01-08-1999
		GR 3030526 T	29-10-1999
		JP 11310600 A	09-11-1999
		JP 9025298 A	28-01-1997
		JP 9506116 T	17-06-1997
		NZ 281469 A	24-04-1997
		US 5985265 A	16-11-1999
		ZA 9501008 A	18-10-1996
WO 9425055 A	10-11-1994	AU 697453 B	08-10-1998
		AU 6778594 A	21-11-1994
		BR 9406490 A	05-03-1996
		CN 1125401 A	26-06-1996
		CZ 9502844 A	14-02-1996
		EP 0744953 A	04-12-1996
		FI 955128 A	27-10-1995

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

P /US 99/27801

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9425055 A		HU 73876 A	28-10-1996
		JP 8509614 T	15-10-1996
		NO 954342 A	30-10-1995
		US 5888772 A	30-03-1999
-----			